Astrazeneca PLC 6-K, filed Feb 9, 2023
Astrazeneca PLC (AZN)
6-K
2023-02-09
For: 2023-02-09
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on February 9, 2023.
|
|
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of February 2023
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
______
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Final
Results
AstraZeneca
9
February 2023 07:00 GMT
Full year and Q4 2022 results
Strong performance and pipeline progress in 2022 underpins 2023
outlook
On track to deliver industry-leading revenue growth through 2025
and beyond
Revenue
and EPS summary
|
|
|
|
FY
2022
|
|
|
Q4
2022
|
|
|
|
|
|
%
Change
|
|
%
Change
|
||
|
|
|
$m
|
Actual
|
CER1
|
$m
|
Actual
|
CER
|
|
-
Product Sales
|
|
42,998
|
18
|
24
|
10,798
|
(6)
|
2
|
|
-
Collaboration Revenue
|
|
1,353
|
54
|
56
|
409
|
(20)
|
(19)
|
|
Total
Revenue
|
|
44,351
|
19
|
25
|
11,207
|
(7)
|
1
|
|
|
$2.12
|
n/m
|
n/m
|
$0.58
|
n/m
|
n/m
|
|
|
Core4 EPS
|
|
$6.66
|
26
|
33
|
$1.38
|
(17)
|
(5)
|
Financial performance (FY 2022 figures
unless otherwise stated, growth numbers and commentary at
CER)
FY 2023 Guidance summary (Growth numbers at
CER)
-
Total Revenue is expected to increase by a low-to-mid single-digit
percentage
Pascal Soriot, Chief Executive Officer, AstraZeneca,
said:
"2022 was a year of continued strong company performance and
execution of our long-term growth strategy. We made excellent
pipeline progress with a record 34 approvals in major markets and
we are initiating new late-stage trials for high potential
medicines such as camizestrant, datopotamab deruxtecan and
volrustomig.
In 2023, we expect to see another year of double-digit revenue
growth at CER, excluding our COVID-19 medicines. We will continue
to invest behind our pipeline and recent launches while continuing
to improve profitability. We plan to initiate more than thirty
Phase III trials this year, of which ten have the potential to
deliver peak year sales over one billion dollars.
Our R&D success and revenue increase in 2022 demonstrate that
we are on track to deliver industry-leading revenue growth through
2025 and beyond, and have set AstraZeneca on a path to deliver at
least fifteen new medicines before the end of the
decade."
Key milestones achieved since the prior results
The
Company provides guidance for FY 2023 at CER, based on the average
exchange rates through 2022.
Total Revenue is expected to increase by a low-to-mid single-digit
percentage
Excluding
COVID-19 medicines, Total Revenue is expected to increase by a low
double-digit percentage
Core EPS is expected to increase by a high single-digit to low
double-digit percentage
The
Company is unable to provide guidance on a Reported basis because
it cannot reliably forecast material elements of the Reported
result, including any fair value adjustments arising on
acquisition-related liabilities, intangible asset impairment
charges and legal settlement provisions. Please refer to the
cautionary statements section regarding forward-looking statements
at the end of this announcement.
Currency impact
If
foreign exchange rates for February to December 2023 were to remain
at the average rates seen in January 2023, it is anticipated that
FY 2023 Total Revenue and FY 2023 Core EPS would both incur a low
single-digit adverse impact versus the performance at
CER.
The
Company's foreign exchange rate sensitivity analysis is provided in
Table 17.
Table 1: Key elements of Total Revenue performance in Q4
2022
|
|
% Change
|
|
|
|
Revenue type
|
|
$m
|
Actual
|
CER
|
|
|
|
Product
Sales
|
|
10,798
|
(6)
|
2
|
|
* Decline of 6% (2% increase at CER) due to lower
sales of Vaxzevria16
* Strong
growth in Oncology, CVRM and Rare Disease
|
|
Collaboration
Revenue
|
|
409
|
(20)
|
(19)
|
|
* $188m for Enhertu (Q4 2021: $60m)
* $37m for Tezspire (Q4 2021: $nil)
* Milestone of $105m for Lynparza
|
|
Total
Revenue
|
|
11,207
|
(7)
|
1
|
|
* Excluding Vaxzevria, Q4 2022 Total Revenue increased by 8% (17% at CER)
- see below
|
|
Therapy areas
|
|
$m
|
Actual
|
CER
|
|
|
|
Oncology
|
|
4,046
|
4
|
12
|
|
* Strong
performance across key medicines and regions
|
|
CVRM6
|
|
2,284
|
12
|
22
|
|
* Farxiga up 39% (52% CER), Lokelma up 50% (63% at CER), roxadustat up 61% (83%
CER), Brilinta decreased 1% (increased 4% at
CER)
|
|
R&I
|
|
1,485
|
(7)
|
(1)
|
|
* Growth in Fasenra, Breztri and Saphnelo offset by decline in Pulmicort of 33% (28% at CER) primarily due to the impact of
VBP17
implementation in
China
|
|
V&I18
|
|
1,163
|
(50)
|
(43)
|
|
* $734m from Evusheld (Q4 2021: $135m)
* $95m from Vaxzevria (Q4 2021: $1,762m)
|
|
Rare
Disease6
|
|
1,816
|
4
|
10
|
|
* Ultomiris up 52% (62% at CER) as gMG launch and conversion
progressed; offset by decline in Soliris
* Strensiq up 24% (27% at CER) reflecting strength of patient
demand and geographic expansion
|
|
Other
Medicines
|
|
412
|
(2)
|
12
|
|
|
|
Total
Revenue
|
|
11,207
|
(7)
|
1
|
|
|
|
Regions inc. Vaxzevria
|
|
$m
|
Actual
|
CER
|
|
|
|
Emerging
Markets
|
|
2,733
|
(25)
|
(18)
|
|
* Decline due to lower sales of Vaxzevria (growth rates excluding Vaxzevria shown below)
|
|
-
China
|
|
1,194
|
(9)
|
3
|
|
* Second
consecutive quarter of growth at CER
|
|
-
Ex-China Emerging Markets
|
|
1,538
|
(35)
|
(29)
|
|
* Decline due to lower sales of Vaxzevria
|
|
US
|
|
4,788
|
22
|
22
|
|
|
|
Europe
|
|
2,308
|
(20)
|
(8)
|
|
* Decline due to lower sales of Vaxzevria
|
|
Established
RoW
|
|
1,378
|
(11)
|
8
|
|
|
|
Total
Revenue inc.
Vaxzevria
|
|
11,207
|
(7)
|
1
|
|
|
|
Regions exc.
Vaxzevria
|
|
$m
|
Actual
|
CER
|
|
|
|
Emerging
Markets
|
|
2,678
|
7
|
18
|
|
|
|
-
China
|
|
1,194
|
(8)
|
4
|
|
* Second
consecutive quarter of growth at CER
|
|
-
Ex-China Emerging Markets
|
|
1,484
|
24
|
33
|
|
* Strong
growth in Oncology and CVRM
* $246m from Evusheld in Q4 (Q4 2021: $69m)
|
|
US
|
|
4,788
|
24
|
24
|
|
*
Growth in Oncology medicines
|
|
Europe
|
|
2,268
|
(12)
|
1
|
|
|
|
Established
RoW
|
|
1,378
|
4
|
27
|
|
|
|
Total
Revenue exc. Vaxzevria
|
|
11,112
|
8
|
17
|
|
|
Table 2: Key elements of financial performance in Q4
2022
|
Metric
|
Reported
|
Reported change
|
Core
|
Core change
|
|
Comments19
|
|
Total
Revenue
|
$11,207m
|
-7%
Actual 1% CER
|
$11,207m
|
-7%
Actual 1% CER
|
|
* Excluding Vaxzevria, Q4 2022 Total Revenue increased by 8% (17% at
CER)
* See
Table 1 and the Total Revenue section of this document for further
details
|
|
Gross
margin20
|
73%
|
13pp
Actual 15pp CER
|
77%
|
3pp
Actual 4pp CER
|
|
+ Increasing mix of
sales from Oncology and Rare Disease medicines
+ Decreasing mix of
Vaxzevria
sales
- Negative impact in
the quarter from currency fluctuations
- Inventory write
downs and manufacturing termination fees relating to Evusheld reduced Gross Profit by $335m
in Q4 2022
- Mix impact from
profit-sharing arrangements (e.g. Lynparza)
- Reported Gross
Margin impacted by unwind of Alexion inventory fair value
adjustment
|
|
R&D
expense
|
$2,625m
|
2%
Actual 9% CER
|
$2,526m
|
5%
Actual 12% CER
|
|
+
Increased
investment in the pipeline
* Core R&D-to-Total Revenue ratio of 23%
(Q4 2021: 20%)
|
|
SG&A
expense
|
$4,621m
|
-10%
Actual -3% CER
|
$3,583m
|
6%
Actual 15% CER
|
|
+ Market
development activities for recent launches
+
Core
SG&A-to-Total Revenue ratio of 32%(Q4 2021: 28%). The
year-on-year comparison is impacted by differences in cost
phasing
during H2 2021 and
H2 2022
|
|
Other
operating income21
|
$189m
|
29%
Actual 33% CER
|
$130m
|
-11%
Actual -7% CER
|
|
* Reported and Core OOI includes income from sale of
the Waltham site
|
|
Operating
margin
|
10%
|
12pp
Actual 14pp CER
|
23%
|
-4pp
Actual -3pp CER
|
|
* See
Gross Margin and Expensescommentary above
|
|
Net
finance expense
|
$315m
|
-6%
Actual stable at CER
|
$245m
|
5%
Actual 9% CER
|
|
* Reported
impacted by a reduction in the discount unwind on
acquisition-related liabilities
|
|
Tax
rate
|
-16%
|
n/m
|
10%
|
-7pp
Actual -6pp CER
|
|
* The Reported and Core Tax Rates in the quarter
reflected IP incentive regimes, geographical mix of profits and adjustments to
prior
year tax liabilities including several one-time
items
*
Variations
in the tax rate can be expected to continue quarter to
quarter
|
|
EPS
|
$0.58
|
n/m
|
$1.38
|
-17%
Actual -5% CER
|
|
* Further
details of differences between Reported and Core are shown in Table
12
|
Table 3: Pipeline highlights since prior results
announcement
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
|
Regulatory
approvals and other regulatory actions
|
Imfinzi +/- Imjudo
|
NSCLC
(1st-line) (POSEIDON)
|
Regulatory
approval (US, JP)
|
|
Imfinzi + Imjudo
|
Hepatocellular
carcinoma (1st-line) (HIMALAYA)
|
Regulatory
approval (JP)
|
|
|
Imfinzi
|
Biliary
tract cancer (TOPAZ-1)
|
Regulatory
approval (EU, JP)
|
|
|
Lynparza
|
mCRPC
(1st-line) (PROpel)
|
Regulatory
approval (EU)
|
|
|
Enhertu
|
HER2-positive
breast cancer (2nd-line) (DESTINY-Breast03)
|
Regulatory
approval (JP)
|
|
|
Enhertu
|
HER2-low
breast cancer (3rd-line) (DESTINY-Breast04)
|
Regulatory
approval (EU)
|
|
|
Enhertu
|
HER2-positive/HER2-low
gastric (2nd-line) (DESTINY-Gastric01,
DESTINY-Gastric02)
|
Regulatory
approval (EU)
|
|
|
Calquence
|
CLL22
(ELEVATE-TN)
|
Regulatory
approval (JP)
|
|
|
|
Calquence
|
Maleate
tablet formulation
|
Regulatory
approval (EU)
|
|
|
Forxiga
|
HFpEF23
(DELIVER)
|
Regulatory
approval (EU, JP)
|
|
|
Airsupra
|
Severe
asthma (MANDALA/DENALI)
|
Regulatory
approval (US)
|
|
|
Tezspire
|
Pre-filled
pen
|
Regulatory
approval (US, EU)
|
|
Regulatory
submissions or acceptances
|
Enhertu
|
HER2-mutated
NSCLC (2nd-line+) (DESTINY-Lung01)
|
Regulatory
submission (EU, JP)
|
|
Calquence
|
CLL
(ASCEND)
|
Regulatory
submission (CN)
|
|
|
Beyfortus
|
RSV24
(MELODY/MEDLEY)
|
Regulatory
submission (US)
|
|
|
Soliris
|
NMOSD25
|
Regulatory
submission (CN)
|
|
|
Major
Phase III data readouts and other developments
|
Imfinzi
|
NSCLC
(1st-line) (PEARL)
|
Primary
endpoint not met
|
|
capivasertib
|
HR26+/HER2-negative
breast cancer (1st-line) (CAPItello-291)
|
Fast
Track Designation (US)
|
|
|
Orpathys + Tagrisso
|
NSCLC
with MET overexpression (SAVANNAH/SAFFRON)
|
Fast
Track Designation (US)
|
|
|
tozorakimab
|
Treatment/prevention
of acute respiratory failure in patients with viral lung infection
(TILIA)
|
Fast
Track Designation (US)
|
|
|
Saphnelo
|
Idiopathic
inflammatory myopathies
|
Orphan
Drug Designation (US)
|
|
|
Evusheld
|
Pre-exposure
prophylaxis of COVID-19
|
Revision
of Emergency Use Authorisation (US) - Evusheld is not currently authorised in
the US until further notice from the FDA27
|
Corporate and business development
In
January 2023, AstraZeneca entered into a definitive agreement to
acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage
biopharmaceutical company focused on developing novel treatments
for resistant and uncontrolled hypertension as well as chronic
kidney disease. The acquisition will bolster AstraZeneca's
cardiorenal pipeline by adding CinCor's candidate drug, baxdrostat
(CIN-107), an aldosterone synthase inhibitor for blood pressure
lowering in treatment-resistant hypertension.
AstraZeneca
has initiated a tender offer to acquire all of CinCor's outstanding
shares for a price of $26 per share in cash at closing, plus a
non-tradable contingent value right of $10 per share in cash
payable upon a specified regulatory submission of a baxdrostat
product. Combined, the upfront and maximum potential contingent
value payments represent, if achieved, a transaction value of
approximately $1.8bn. As part of the transaction, AstraZeneca will
acquire the cash and marketable securities on CinCor's balance
sheet, which totalled approximately $522m as of 30 September
2022.
In
January 2023, AstraZeneca completed the acquisition of Neogene
Therapeutics Inc. (Neogene), a global clinical-stage biotechnology
company pioneering the discovery, development and manufacturing of
next-generation T-cell receptor therapies that offer a novel cell
therapy approach for targeting cancer. AstraZeneca acquired
outstanding equity of Neogene for a total consideration of up to
$320m, on a cash and debt free basis. This includes an initial
payment of $200m on deal closing, and a further up to $120m in both
contingent milestones-based and non-contingent
consideration.
Following
the approval of Airsupra in
January 2023, AstraZeneca has notified Avillion of its intention to
commercialise Airsupra in
the US. Under the terms of the agreement with Avillion, AstraZeneca
will pay single-digit royalties and milestones based on future
sales and developments.
In
December 2022, AstraZeneca completed the sale of its R&D
facility in Waltham, Massachusetts, US, to Alexandria Real Estate
Equities, Inc, (ARE), a leading owner, operator and developer of
life science campuses. ARE will lease the site back to AstraZeneca
for a four-year term while construction is being completed on the
new AstraZeneca R&D Centre and Alexion Headquarters in Kendall
Square, Cambridge, Massachusetts, announced in April
2022.
In
January 2023, AstraZeneca completed the sale of its West Chester
site in Ohio, US, to National Resilience, Inc., a
technology-focused manufacturing company dedicated to broadening
access to complex medicines. The West Chester site will continue to
manufacture medicines for AstraZeneca.
Post Alexion Acquisition Group Review (PAAGR)
In
conjunction with the acquisition of Alexion in 2021, AstraZeneca
initiated a comprehensive review, aimed at integrating systems,
structure and processes, optimising the global footprint and
prioritising resource allocations and investments. These activities
are expected to be substantially complete by the end of 2025, with
a number of planned activities having commenced in late 2021 and
during 2022.
During
2022, the Company has refined the scope and estimates of the
planned activities, resulting in an increase to the expected
one-time restructuring costs over the life of the programme of
$0.5bn, of which $0.3bn are non-cash costs, an increase in capital
investments of $0.1bn, and an increase to the anticipated annual
run-rate pre-tax benefits by the end of 2025 of
$0.7bn.
In
addition, initial financial estimates for the Company's planned
upgrade of its Enterprise Resource Planning IT systems have been
completed, resulting in anticipated incremental capital investments
for software assets of $0.6bn and one-time restructuring cash costs
of $0.3bn. This investment builds strongly on the PAAGR and is
expected to be substantially complete by the end of 2030, realising
significant strategic and compliance-related benefits from
transforming core enterprise-wide processes, harmonising systems
architecture and enabling future digital capabilities.
Consequently,
the total programme activities are now anticipated to incur
one-time restructuring costs of approximately $2.9bn, of which
approximately $1.9bn are cash costs and $1.0bn are non-cash costs,
and capital investments of approximately $0.9bn.
Run-rate
pre-tax benefits, before reinvestment, are now expected to be
approximately $1.9bn by the end of 2025. In line with established
practice, restructuring costs will be excluded from our Core
(non-GAAP) financial measures.
During
2022, AstraZeneca recorded restructuring charges of approximately
$0.7bn in relation to the PAAGR (2021: $1.0bn), bringing the
cumulative charges to date under this programme to $1.7bn. Of these
costs, $0.7bn are non-cash costs arising primarily from impairments
and accelerated depreciation on affected assets. As at 31 December
2022, the PAAGR has realised annual run-rate pre-tax benefits,
before reinvestment, of $0.8bn.
Sustainability summary
In
November 2022, AstraZeneca achieved third position overall in the
2022 Access to Medicine Index.
In
January 2023, Chair Leif Johansson alongside Senior Executive Team
members Marc Dunoyer, Dave Fredrickson and Iskra Reic attended the
World Economic Forum in Davos, focusing on investing in health as
the foundation of strong and resilient societies, and the need for
collective early action to build more sustainable and equitable
healthcare systems, including through collaborations such as the
Partnership for Health System Sustainability and Resilience and the
Sustainable Markets Initiative.
Management changes
Katarina
Ageborg, EVP Global Sustainability and Chief Compliance Officer,
has announced her retirement. Jeffrey Pott, Chief Human Resources
Officer and General Counsel, will assume responsibility as Chief
Compliance Officer in addition to his current responsibilities. Pam
Cheng, Executive Vice-President, Operations and Information
Technology, will assume responsibility for leadership of
Sustainability strategy and function in addition to her existing
responsibilities. The Board thanks Katarina for her lasting legacy,
having positioned AstraZeneca amongst the global leaders in
sustainability, backed by world-leading platforms and science-based
targets.
Conference call
A
conference call and webcast for investors and analysts will begin
today, 9 February 2023, at 11:45 GMT. Details can be accessed via
astrazeneca.com.®
Reporting calendar
The
Company intends to publish its results for the first quarter of
2023 on Thursday 27 April 2023.
Operating and financial review
All
narrative on growth and results in this section is based on actual
exchange rates, and financial figures are in US$ millions ($m),
unless stated otherwise. Unless stated otherwise, the performance
shown in this announcement covers the twelve-month period to 31
December 2022 ('the year' or 'FY 2022') compared to the
twelve-month period to 31 December 2021 (FY 2021), or the
three-month period to 31 December 2022 ('the fourth quarter' or 'Q4
2022') compared to the three-month period to 31 December 2021 ('Q4
2021').
Core
financial measures, EBITDA, Net Debt, Gross Margin, Operating
Margin and CER are non-GAAP financial measures because they cannot
be derived directly from the Group's Condensed Consolidated
Financial Statements. Management believes that these non-GAAP
financial measures, when provided in combination with Reported
results, provide investors and analysts with helpful supplementary
information to understand better the financial performance and
position of the Group on a comparable basis from period to period.
These non-GAAP financial measures are not a substitute for, or
superior to, financial measures prepared in accordance with
GAAP.
Core
financial measures are adjusted to exclude certain significant
items, such as:
Details
on the nature of Core financial measures are provided on page 54 of
the Annual
Report and Form 20-F Information 2021.
Reference
should be made to the Reconciliation of Reported to Core financial
measures table included in the financial performance section in
this announcement.
Gross
Margin, previously termed Gross Profit Margin, is the percentage by
which Product Sales exceeds the Cost of sales, calculated by
dividing the difference between the two by the sales figure. The
calculation of Reported and Core Gross Margin excludes the impact
of Collaboration Revenue and any associated costs, thereby
reflecting the underlying performance of Product
Sales.
EBITDA
is defined as Reported Profit before tax after adding back Net
finance expense, results from Joint Ventures and Associates and
charges for Depreciation, Amortisation and Impairment. Reference
should be made to the Reconciliation of Reported Profit before tax
to EBITDA included in the financial performance section in this
announcement.
Net
Debt is defined as Interest-bearing loans and borrowings and Lease
liabilities, net of Cash and cash equivalents, Other investments,
and net derivative financial instruments. Reference should be made
to Note 3 'Net Debt' included in the Notes to the Condensed
Consolidated Financial Statements in this
announcement.
The
Company strongly encourages investors and analysts not to rely on
any single financial measure, but to review AstraZeneca's financial
statements, including the Notes thereto, and other available
Company reports, carefully and in their entirety.
Due to
rounding, the sum of a number of dollar values and percentages in
this announcement may not agree to totals.
Total Revenue
Table 4: Therapy area and medicine performance
|
|
|
FY 2022
|
Q4 2022
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
Product Sales
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
14,631
|
33
|
13
|
19
|
3,746
|
33
|
9
|
18
|
|
-
Tagrisso
|
|
5,444
|
12
|
9
|
15
|
1,342
|
12
|
2
|
12
|
|
-
Imfinzi 28
|
|
2,784
|
6
|
15
|
21
|
752
|
7
|
19
|
27
|
|
-
Lynparza
|
|
2,638
|
6
|
12
|
18
|
689
|
6
|
10
|
17
|
|
-
Calquence
|
|
2,057
|
5
|
66
|
69
|
588
|
5
|
49
|
53
|
|
-
Enhertu
|
|
79
|
-
|
>4x
|
>4x
|
28
|
-
|
>3x
|
>3x
|
|
-
Orpathys
|
|
33
|
-
|
>2x
|
>2x
|
(1)
|
-
|
n/m
|
n/m
|
|
-
Zoladex
|
|
927
|
2
|
(2)
|
6
|
210
|
2
|
(9)
|
4
|
|
-
Faslodex
|
|
334
|
1
|
(22)
|
(14)
|
74
|
1
|
(27)
|
(14)
|
|
-
Iressa
|
|
114
|
-
|
(38)
|
(34)
|
24
|
-
|
(32)
|
(24)
|
|
-
Arimidex
|
|
99
|
-
|
(29)
|
(24)
|
14
|
-
|
(57)
|
(50)
|
|
-
Casodex
|
|
78
|
-
|
(45)
|
(40)
|
16
|
-
|
(28)
|
(16)
|
|
-
Others
|
|
44
|
-
|
(14)
|
(6)
|
10
|
-
|
(29)
|
(18)
|
|
BioPharmaceuticals: CVRM 6
|
|
9,188
|
21
|
13
|
19
|
2,281
|
20
|
12
|
22
|
|
-
Farxiga
|
|
4,381
|
10
|
46
|
56
|
1,177
|
11
|
39
|
52
|
|
-
Brilinta
|
|
1,358
|
3
|
(8)
|
(4)
|
345
|
3
|
(1)
|
4
|
|
-
Lokelma
|
|
289
|
1
|
65
|
75
|
81
|
1
|
50
|
63
|
|
-
Roxadustat
|
|
197
|
-
|
13
|
18
|
49
|
-
|
65
|
87
|
|
-
Andexxa 6
|
|
150
|
-
|
5
|
14
|
39
|
-
|
-
|
14
|
|
-
Crestor
|
|
1,048
|
2
|
(4)
|
2
|
224
|
2
|
(13)
|
(2)
|
|
-
Seloken/Toprol-XL
|
|
862
|
2
|
(9)
|
(4)
|
157
|
1
|
(23)
|
(12)
|
|
-
Bydureon
|
|
280
|
1
|
(27)
|
(26)
|
73
|
1
|
(20)
|
(20)
|
|
-
Onglyza
|
|
257
|
1
|
(28)
|
(25)
|
52
|
-
|
(31)
|
(24)
|
|
-
Others
|
|
366
|
1
|
(10)
|
(7)
|
84
|
1
|
(13)
|
(6)
|
|
BioPharmaceuticals:
R&I
|
|
5,765
|
13
|
(4)
|
-
|
1,447
|
13
|
(9)
|
(3)
|
|
-
Symbicort
|
|
2,538
|
6
|
(7)
|
(2)
|
620
|
6
|
(9)
|
(2)
|
|
-
Fasenra
|
|
1,396
|
3
|
11
|
15
|
381
|
3
|
7
|
12
|
|
-
Breztri
|
|
398
|
1
|
96
|
>2x
|
116
|
1
|
59
|
68
|
|
-
Saphnelo
|
|
116
|
-
|
>10x
|
>10x
|
48
|
-
|
>6x
|
>6x
|
|
-
Tezspire
|
|
4
|
-
|
n/m
|
n/m
|
4
|
-
|
n/m
|
n/m
|
|
-
Pulmicort
|
|
645
|
1
|
(33)
|
(31)
|
166
|
1
|
(33)
|
(28)
|
|
-
Daliresp/Daxas
|
|
189
|
-
|
(17)
|
(16)
|
28
|
-
|
(52)
|
(52)
|
|
-
Bevespi
|
|
58
|
-
|
7
|
9
|
14
|
-
|
(5)
|
(1)
|
|
- Others
|
|
421
|
1
|
(29)
|
(27)
|
70
|
1
|
(53)
|
(47)
|
|
BioPharmaceuticals:
V&I
|
|
4,736
|
11
|
2
|
8
|
1,129
|
10
|
(51)
|
(44)
|
|
-
Vaxzevria
|
|
1,798
|
4
|
(54)
|
(52)
|
85
|
1
|
(95)
|
(94)
|
|
-
Evusheld
|
|
2,185
|
5
|
>10x
|
>10x
|
734
|
7
|
>8x
|
>9x
|
|
-
Synagis
|
|
578
|
1
|
41
|
59
|
194
|
2
|
(19)
|
(3)
|
|
-
FluMist
|
|
175
|
-
|
(31)
|
(20)
|
116
|
1
|
(35)
|
(24)
|
|
Rare Disease 6
|
|
7,053
|
16
|
4
|
10
|
1,816
|
16
|
4
|
10
|
|
- Soliris 6
|
|
3,762
|
8
|
(11)
|
(5)
|
844
|
8
|
(22)
|
(16)
|
|
- Ultomiris 6
|
|
1,965
|
4
|
34
|
42
|
593
|
5
|
52
|
62
|
|
- Strensiq 6
|
|
958
|
2
|
16
|
18
|
272
|
2
|
24
|
27
|
|
-
Koselugo
|
|
208
|
-
|
93
|
96
|
58
|
1
|
74
|
77
|
|
-
Kanuma 6
|
|
160
|
-
|
16
|
19
|
49
|
-
|
45
|
44
|
|
Other
Medicines
|
|
1,625
|
4
|
(5)
|
4
|
379
|
3
|
(7)
|
7
|
|
-
Nexium
|
|
1,285
|
3
|
(3)
|
8
|
300
|
3
|
(9)
|
7
|
|
- Others
|
|
340
|
1
|
(10)
|
(7)
|
79
|
1
|
(1)
|
5
|
|
Product Sales
|
|
42,998
|
97
|
18
|
24
|
10,798
|
96
|
(6)
|
2
|
|
Collaboration Revenue
|
|
1,353
|
3
|
54
|
56
|
409
|
4
|
(20)
|
(19)
|
|
Total Revenue
|
|
44,351
|
100
|
19
|
25
|
11,207
|
100
|
(7)
|
1
|
Table 5: Collaboration Revenue
|
|
|
FY 2022
|
Q4 2022
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Enhertu: alliance revenue 29
|
|
519
|
38
|
>2x
|
>2x
|
187
|
46
|
>3x
|
>3x
|
|
Tezspire: alliance revenue
|
|
79
|
6
|
n/m
|
n/m
|
37
|
9
|
n/m
|
n/m
|
|
Lynparza: regulatory milestones
|
|
355
|
26
|
n/m
|
n/m
|
105
|
26
|
n/m
|
n/m
|
|
Tralokinumab:
sales milestones
|
|
110
|
8
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
|
Vaxzevria: royalties
|
|
76
|
6
|
19
|
16
|
10
|
2
|
n/m
|
n/m
|
|
Other
royalty income
|
|
72
|
5
|
(42)
|
(41)
|
17
|
4
|
(75)
|
(74)
|
|
Other
Collaboration Revenue
|
|
142
|
10
|
49
|
69
|
53
|
13
|
>10x
|
>10x
|
|
Total
|
|
1,353
|
100
|
54
|
56
|
409
|
100
|
(20)
|
(19)
|
Table 6: Total Revenue by therapy area
|
|
|
FY 2022
|
Q4 2022
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
15,539
|
35
|
15
|
20
|
4,046
|
36
|
4
|
12
|
|
BioPharmaceuticals
6
|
|
20,010
|
45
|
5
|
11
|
4,932
|
44
|
(17)
|
(9)
|
|
- CVRM6
|
|
9,211
|
21
|
13
|
19
|
2,284
|
20
|
12
|
22
|
|
- R&I
|
|
5,963
|
13
|
(1)
|
3
|
1,485
|
13
|
(7)
|
(1)
|
|
- V&I
|
|
4,836
|
11
|
1
|
8
|
1,163
|
10
|
(50)
|
(43)
|
|
Rare
Disease6
|
|
7,053
|
16
|
4
|
10
|
1,816
|
16
|
4
|
10
|
|
Other
Medicines
|
|
1,748
|
4
|
(4)
|
5
|
412
|
4
|
(2)
|
12
|
|
Total
|
|
44,351
|
100
|
19
|
25
|
11,207
|
100
|
(7)
|
1
|
Table 7: Total Revenue by region
|
|
|
FY 2022
|
Q4 2022
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Emerging
Markets
|
|
11,745
|
26
|
(4)
|
1
|
2,733
|
24
|
(25)
|
(18)
|
|
- China
|
|
5,792
|
13
|
(4)
|
-
|
1,194
|
11
|
(9)
|
3
|
|
- Ex-China
|
|
5,953
|
13
|
(5)
|
1
|
1,538
|
14
|
(35)
|
(29)
|
|
US
|
|
17,920
|
40
|
47
|
47
|
4,788
|
43
|
22
|
22
|
|
Europe
|
|
8,738
|
20
|
9
|
21
|
2,308
|
21
|
(20)
|
(8)
|
|
Established
RoW
|
|
5,948
|
13
|
22
|
40
|
1,378
|
12
|
(11)
|
8
|
|
Total
|
|
44,351
|
100
|
19
|
25
|
11,207
|
100
|
(7)
|
1
|
Table 8: Total Revenue by region -
excluding Vaxzevria
|
|
|
FY 2022
|
Q4 2022
|
||||||
|
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Emerging
Markets
|
|
10,940
|
25
|
10
|
16
|
2,678
|
24
|
7
|
18
|
|
- China
|
|
5,746
|
13
|
(4)
|
(1)
|
1,194
|
11
|
(8)
|
4
|
|
- Ex-China
|
|
5,195
|
12
|
31
|
41
|
1,484
|
13
|
24
|
33
|
|
US
|
|
17,840
|
40
|
47
|
47
|
4,788
|
43
|
24
|
24
|
|
Europe
|
|
8,372
|
19
|
19
|
33
|
2,268
|
20
|
(12)
|
1
|
|
Established
RoW
|
|
5,323
|
12
|
24
|
43
|
1,378
|
12
|
4
|
27
|
|
Total
|
|
42,476
|
96
|
27
|
34
|
11,112
|
99
|
8
|
17
|
Oncology
Oncology
Total Revenue increased by 15% (20% at CER) in FY 2022 to $15,539m
and represented 35% of overall Total Revenue (FY 2021: 36%). This
included Lynparza
Collaboration Revenue of $355m (FY 2021: $400m) and
Enhertu Collaboration
Revenue of $523m (FY 2021: $197m). Product Sales increased by 13%
(19% at CER) in FY 2022 to $14,631m, reflecting new launches and
increased patient access for Tagrisso, Imfinzi, Lynparza and Calquence partially offset by declines
in some older medicines.
Tagrisso
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
5,444
|
|
1,567
|
2,007
|
1,023
|
847
|
|
Actual
change
|
|
9%
|
|
17%
|
13%
|
4%
|
(7%)
|
|
CER
change
|
|
15%
|
|
22%
|
13%
|
17%
|
8%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Increased use of Tagrisso in adjuvant and 1st-line setting and expansion of
reimbursed access, partially offset by COVID-19
headwinds
|
|
Emerging
Markets
|
|
* Rising demand from increased patient access in
China continues to offset the impact of the March 2021
NRDL30 price
reduction
* The
fourth quarter saw some impact from year-end ordering dynamics in
China
|
|
US
|
|
* Improving
use in 1st-line with longer duration of treatment and increasing
adjuvant penetration, partially offset by lower 2nd-line
use
|
|
Europe
|
|
* Greater use in 1st-line and adjuvant settings;
established 1st-line standard of care in EU531, partially
offset by lower 2nd-line use
|
|
Established
RoW
|
|
* Increased
use in 1st-line setting and launch progress in adjuvant, including
Japan
|
Imfinzi
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
2,784
|
|
287
|
1,552
|
544
|
401
|
|
Actual
change
|
|
15%
|
|
4%
|
25%
|
12%
|
(1%)
|
|
CER
change
|
|
21%
|
|
7%
|
25%
|
26%
|
15%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* The Imfinzi revenue line includes sales of Imjudo, which commenced in Q4 2022 following approvals in
the US for patients with unresectable liver cancer (HIMALAYA) and
Stage IV NSCLC (POSEIDON)
* Increased use of Imfinzi in
GI, liver and lung cancer
* Continued
recovery in diagnosis and treatment rates following the COVID-19
pandemic across all regions, excluding China
|
|
Emerging
Markets
|
|
* Growth
in ex-China driven by improved diagnosis and treatment rates
following the COVID-19 pandemic
|
|
US
|
|
* New patient starts across Stage III NSCLC and
ES-SCLC32
* Strong launch in BTC33 following
September 2022 FDA approval (TOPAZ-1), and growing penetration
of Imfinzi + Imjudo in metastatic NSCLC and HCC
|
|
Europe
|
|
* Increased
market penetration in ES-SCLC, growth in the number of reimbursed
markets, and ongoing recovery in rates of diagnosis and
treatment
|
|
Established
RoW
|
|
* New
reimbursements
|
Lynparza
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
2,993
|
|
488
|
1,226
|
1,010
|
269
|
|
Actual
change
|
|
9%
|
|
27%
|
13%
|
(1%)
|
4%
|
|
CER
change
|
|
14%
|
|
31%
|
13%
|
7%
|
20%
|
|
Product
Sales
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
2,638
|
|
488
|
1,226
|
655
|
269
|
|
Actual
change
|
|
12%
|
|
27%
|
13%
|
6%
|
4%
|
|
CER
change
|
|
18%
|
|
31%
|
13%
|
19%
|
20%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Lynparza remains the leading medicine in the
PARP34 inhibitor
class globally across four tumour types, as measured by total
prescription volume
* Total Revenue includes $355m in regulatory
milestones received from MSD and recognised in Europe, following
approval in the US and EU for the adjuvant treatment of patients
with gBRCAm35 breast
cancer (OlympiA), and approval in the EU for the treatment of mCRPC
(PROpel)
|
|
Emerging
Markets
|
|
* Increased patient access following admission to
China's NRDL as a 1st-line maintenance treatment for
BRCAm36 ovarian
cancer patients, with effect from March 2021; launches in other
markets
|
|
US
|
|
* US
launch in early breast cancer following March 2022 FDA approval
(OlympiA)
* Increased
use in breast, ovarian and prostate cancers
|
|
Europe
|
|
*
Increasing HRD testing rates and use in 1st-line
HRD-positive ovarian cancer, increased Lynparza uptake in BRCAm mCRPC37 and gBRCAm
HER2-negative advanced breast cancer and the EU launch in gBRCAm
early breast cancer following EMA38 approval
in August (OlympiA)
|
|
Established
RoW
|
|
*
New
launches and high levels of HRD testing in Japan
|
Enhertu
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
602
|
|
80
|
405
|
110
|
7
|
|
Actual
change
|
|
>2x
|
|
>6x
|
>2x
|
>3x
|
>10x
|
|
CER
change
|
|
>2x
|
|
>6x
|
>2x
|
>3x
|
>10x
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Excluding Japan, Enhertu global in-market sales recorded by Daiichi Sankyo
Company Limited (Daiichi Sankyo) and AstraZeneca, amounted to
$1,173m in the year (FY 2021: $426m)
* AstraZeneca's
Total Revenue of $602m includes $523m of Collaboration Revenue from
its share of gross profit in territories where Daiichi Sankyo
records product sales and royalties on sales in Japan
|
|
Emerging
Markets
|
|
* Strong
uptake in early launch markets
|
|
US
|
|
* US
in-market sales, recorded by Daiichi Sankyo, amounted to $850m in
the year (FY 2021: $357m)
* Now
standard of care in 2nd-line HER2-positive metastatic breast cancer
following May 2022 FDA approval (DESTINY-Breast03) and after first
chemotherapy in HER2-low metastatic breast cancer following August
2022 FDA approval (DESTINY-Breast04)
|
|
Europe
|
|
* Growth
in 3rd-line+ HER2-positive metastatic breast and launch in 2nd-line
HER2-positive metastatic breast cancer after EMA approval in July
2022 (DESTINY-Breast03)
|
|
Established
RoW
|
|
* In
Japan, AstraZeneca receives a mid-single-digit percentage royalty
on sales made by Daiichi Sankyo
|
Calquence
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
2,057
|
|
45
|
1,657
|
286
|
69
|
|
Actual
change
|
|
66%
|
|
>2x
|
52%
|
>2x
|
>3x
|
|
CER
change
|
|
69%
|
|
>2x
|
52%
|
>2x
|
>4x
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Increased penetration globally; leading
BTKi39 in key
markets
|
|
US
|
|
* Increased
share of new patient starts
* Inventory
build in Q3 following maleate tablet formulation launch in August;
Q4 observed partial inventory work down
|
|
Europe
|
|
* Increased
share of new patient starts
|
Orpathys
Total
Revenue of $33m (FY 2021: $16m), growth was driven by the 2021
launch in China, where it is approved for patients with lung cancer
and MET gene alterations. Orpathys has been included in the
updated NRDL in China for the treatment of patients with NSCLC with
MET exon 14 skipping alterations. The updated NRDL will take effect
from 1 March 2023.
Other Oncology medicines
|
|
FY
2022
|
%
Change
|
|
|
Total
Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Zoladex
|
|
957
|
(1%)
|
7%
|
Increased
use in ex-China Emerging Markets, offsetting a price cut in
Japan
|
|
Faslodex
|
|
334
|
(22%)
|
(14%)
|
Generic
competition
|
|
Iressa
|
|
114
|
(38%)
|
(34%)
|
Continued
share loss to next-generation TKIs40
|
|
Arimidex
|
|
99
|
(29%)
|
(24%)
|
|
|
Casodex
|
|
78
|
(45%)
|
(40%)
|
Ongoing
impact from VBP implementation
|
|
Other
Oncology
|
|
44
|
(14%)
|
(6%)
|
|
BioPharmaceuticals
Including
V&I medicines, BioPharmaceuticals Total Revenue increased by 5%
(11% at CER) in FY 2022 to $20,010m, representing 45% of overall
Total Revenue (FY 2021: 51%). Growth was driven by strong
Farxiga performance,
Evusheld revenues
offsetting the decline in Vaxzevria, and growth from newer
R&I medicines offsetting decreases in Pulmicort and other older R&I
medicines.
BioPharmaceuticals - CVRM
CVRM
Total Revenue increased by 13% (19% at CER) to $9,211m in FY 2022,
driven by a strong Farxiga
performance, and represented 21% of overall Total Revenue (FY 2021:
22%).
Farxiga
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
4,386
|
|
1,665
|
1,071
|
1,297
|
353
|
|
Actual
change
|
|
46%
|
|
39%
|
46%
|
60%
|
31%
|
|
CER
change
|
|
56%
|
|
47%
|
46%
|
81%
|
48%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Farxiga volume is growing faster than the overall
SGLT241 market in
all major regions
* Additional
benefit from continued growth in the overall SGLT2 inhibitor
class
* Further HF42 and CKD
launches and supportive updates to treatment guidelines including
from ESC43 and
AHA44/ACC45/HFSA46.
HF and CKD indications now launched in >100
markets
|
|
Emerging
Markets
|
|
* Growth
despite generic competition in some markets. Solid growth in
ex-China Emerging Markets, particularly Latin America
|
|
US
|
|
* Regulatory approval for HFrEF47 in May
2020, treatment of CKD in May 2021. Both approvals included
patients with and without T2D48
* Farxiga continued to gain in-class brand share, driven by
HF and CKD launches
|
|
Europe
|
|
* The
beneficial addition of cardiovascular outcomes trial data to the
label, the HFrEF regulatory approval in November 2020, and CKD
regulatory approval in August 2021
* Forxiga continued gaining in-class market share in the
period
|
|
Established
RoW
|
|
* In
Japan, AstraZeneca sells to collaborator Ono Pharmaceutical Co.,
Ltd, which records in-market sales. Continued volume growth driven
by HF and CKD launches
|
Brilinta
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
1,358
|
|
286
|
744
|
282
|
46
|
|
Actual
change
|
|
(8%)
|
|
(13%)
|
1%
|
(18%)
|
(27%)
|
|
CER
change
|
|
(4%)
|
|
(10%)
|
1%
|
(8%)
|
(22%)
|
|
Region
|
|
Drivers
and commentary
|
|
Emerging
Markets
|
|
* Adverse impact from Brilinta's inclusion in China's VBP
programme
* Growth
in ex-China Emerging Markets
|
|
US,
Europe
|
|
* Q4
US sales growth favourably impacted by a one-time adjustment. Some
market recovery of oral antiplatelet therapies following the
pandemic
|
Lokelma
Total
Revenue increased 65% (75% at CER) to $289m in FY 2022, driven by
Lokelma extending its
branded market share lead in the US and also achieving total
potassium binder market share leadership in the period. Continued
progress in Europe from recent launches across the region where
Lokelma extended its market
share in the period. In China, Lokelma was admitted to the NRDL with
effect from 1 January 2022 and is now the leading potassium binder
in the country.
Roxadustat
Total
Revenue increased 12% (17% at CER) to $202m, with roxadustat
benefitting from increased volumes in China following NRDL price
cuts.
Andexxa
On a
pro forma basis, Andexxa
Total Revenue increased 12% (21% at CER) to $160m.
Other CVRM medicines
|
|
FY
2022
|
%
Change
|
|
|
Total
Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Crestor
|
|
1,050
|
(4%)
|
2%
|
* Sales
growth at CER driven by Emerging Markets, offset by declines in the
US and Europe
|
|
Seloken
|
|
863
|
(9%)
|
(4%)
|
* Emerging Markets sales impacted by China VBP
implementation of Betaloc49 oral in H2
2021. Betaloc ZOK VBP was implemented in Q4 2022
|
|
Onglyza
|
|
257
|
(28%)
|
(25%)
|
* Ongoing
impact from VBP implementation
|
|
Bydureon
|
|
280
|
(27%)
|
(26%)
|
* Continued
competitive pressures
|
|
Other
CVRM
|
|
366
|
(10%)
|
(7%)
|
|
BioPharmaceuticals - R&I
Total
Revenue of $5,963m from R&I medicines in FY 2022 decreased 1%
(increased 3% at CER) and represented 13% of overall Total Revenue
(FY 2021: 16%). This reflected growth in recently launched brands,
including Fasenra,
Tezspire, Breztri and Saphnelo, offset by the erosion of
Pulmicort revenue following
its inclusion in VBP in China in Q4 2021, and a smaller decline in
Symbicort
revenue.
Symbicort
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
2,538
|
|
608
|
973
|
582
|
375
|
|
Actual
change
|
|
(7%)
|
|
-
|
(9%)
|
(13%)
|
(2%)
|
|
CER
change
|
|
(2%)
|
|
5%
|
(9%)
|
(3%)
|
5%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
|
|
Emerging
Markets
|
|
*
Growth
driven primarily by Latin America, Middle East and Asia Area,
offset by decrease in China due to COVID-19
restrictions
|
|
US
|
|
* Strong
market share performance, consolidating leadership in a declining
ICS/LABA market, offset by pricing pressure
|
|
Europe
|
|
* Resilient
market share in growing ICS/LABA market, offset by pricing
pressure
|
|
Established
RoW
|
|
* Growth
in some countries driven by share gains and a continued recovery in
the ICS/LABA market. That growth was offset by generic erosion in
other countries
|
Fasenra
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
1,396
|
|
43
|
906
|
305
|
142
|
|
Actual
change
|
|
11%
|
|
>2x
|
15%
|
7%
|
(12%)
|
|
CER
change
|
|
15%
|
|
>2x
|
15%
|
20%
|
(1%)
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Fasenra continues to be market leader in severe
eosinophilic asthma in major markets, and leading in the
IL-552 class
|
|
Emerging
Markets
|
|
* Strong
volume growth driven by launch acceleration across key
markets
|
|
US
|
|
* Maintained
a strong total patient share in the severe asthma
market
|
|
Europe
|
|
* Sustained
growth by expanding leadership in severe eosinophilic
asthma
|
|
Established
RoW
|
|
* Maintained market leadership in Japan, partially
offset by price adjustments and impact in the dynamic
market53 related to
the rise in COVID-19 cases
|
Breztri
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
398
|
|
92
|
239
|
33
|
34
|
|
Actual
change
|
|
96%
|
|
68%
|
>2x
|
>4x
|
32%
|
|
CER
change
|
|
>2x
|
|
75%
|
>2x
|
>5x
|
56%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Breztri continued to gain market share within the growing
FDC54
triple class across major
markets
|
|
Emerging
Markets
|
|
* In China, the FDC triple class continued to
penetrate the inhaled maintenance market, with growth impacted by
COVID-19. Breztri continued its market share leadership within the
fixed-dose triple class
|
|
US
|
|
* Consistent new-to-brand55 and total
market share growth within the FDC triple class
|
|
Europe
|
|
* Sustained
growth across markets as new launches continue to
progress
|
|
Established
RoW
|
|
* Strong
new-to-brand market share performance in Japan, with the dynamic
market impacted by access restrictions related to the rise in
COVID-19 cases
|
Saphnelo
Total
Revenue of $116m in the year (FY 2021: $8m) was driven by demand
acceleration in the US, where Saphnelo achieved new-to-brand
leadership in the i.v.56 segment for SLE57 and received a permanent J-code
facilitating reimbursement. Growth was further supported by
launches in Germany and Japan during the year.
Tezspire
Tezspire is approved in the US, EU and Japan (as well as
other countries) for the treatment of severe asthma without
biomarker or phenotypic limitation. Collaboration Revenue of $82m
in the year (FY 2021: $nil) reflected the strong early launch
performance in the US. In Europe and Established RoW, AstraZeneca
recorded $4m revenue ($2m in each region).
Amgen
records sales in the US and AstraZeneca records its share of gross
profits in the US as Collaboration Revenue. Total ex-US product
sales are recorded as AstraZeneca revenue ($4m in 2022). Global
in-market sales of Tezspire
were $174m in 2022.
Other R&I medicines
|
|
FY
2022
|
%
Change
|
|
|
Total
Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Pulmicort
|
|
645
|
(33%)
|
(31%)
|
* Emerging
Markets revenue decreased 40% (39% at CER) to $462m, impacted by
VBP implementation in China, lower rates of hospitalisations and
limited access to nebulisation centres in China due to COVID-19
lockdowns
* Revenues
in Ex-China Emerging Markets grew following recovery of
nebulisation demand
|
|
Daliresp/Daxas
|
|
189
|
(17%)
|
(16%)
|
* Impacted
by uptake of multiple generics following loss of exclusivity in the
US
* Total
Revenue in the fourth quarter decreased by 52%
|
|
Bevespi
|
|
58
|
7%
|
9%
|
|
|
Other
R&I
|
|
540
|
(11%)
|
(9%)
|
* Collaboration
Revenue of $119m (FY 2021: $15m), including $110m of milestones
relating to tralokinumab (FY 2021: $nil)
*Product
Sales of $421m decreased 29% (27% at CER)
|
BioPharmaceuticals - V&I
Total
Revenue from V&I medicines was broadly flat at $4,836m (FY
2021: $4,779m) and represented 11% of overall Total Revenue (FY
2021: 13%).
Vaxzevria
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
1,875
|
|
805
|
79
|
365
|
625
|
|
Actual
change
|
|
(53%)
|
|
(65%)
|
24%
|
(65%)
|
8%
|
|
CER
change
|
|
(51%)
|
|
(65%)
|
24%
|
(61%)
|
17%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
*
Revenue in the fourth quarter decreased by 95%
(94% at CER) due to the conclusion of Vaxzevria contracts
|
|
Emerging
Markets
|
|
*
$76m
of Collaboration Revenue from sub-licensees in FY 2022, including
$46m in Q1 2022 from a Chinese sub-licensee producing vaccines for
export
* Revenue
in the fourth quarter decreased by 95%
|
|
US
|
|
* Purchases
by the US Government for donation overseas in Q1 2022
* No
revenue was recorded after Q1 2022
|
|
Europe
|
|
* Revenue
in the fourth quarter decreased by 87% (84% at CER) vs Q4
2021
|
|
Established
RoW
|
|
* No
revenue was recorded for Established RoW in the fourth
quarter
|
Evusheld
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
2,184
|
|
413
|
1,067
|
298
|
407
|
|
Actual
change
|
|
>10x
|
|
>6x
|
n/m
|
>4x
|
n/m
|
|
CER
change
|
|
>10x
|
|
>6x
|
n/m
|
>5x
|
n/m
|
|
Region
|
|
Drivers
and commentary
|
|
US
|
|
* AstraZeneca
fulfilled the US Government's order for 1.7 million units during
the year
|
|
Emerging
Markets
|
|
* Government
contracts in Central and Eastern Europe, Latin America and South
East Asia
|
|
Europe
|
|
* Approved
in the EU for prevention of COVID-19 in March 2022 and treatment of
COVID-19 in September 2022
|
|
Established
RoW
|
|
* Approved
in Japan for prevention and treatment of COVID-19 in August
2022
|
Other V&I medicines
|
|
FY
2022
|
%
Change
|
|
|
Total
Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Synagis
|
|
578
|
41%
|
59%
|
* Ex-US
rights reverted to AstraZeneca after 30 June 2021, from AbbVie
Inc.
* In Q4 2022, Synagis sales decreased by 19% (3% CER), reflecting the
early start to the RSV season in the prior year
period
|
|
FluMist
|
|
175
|
(31%)
|
(20%)
|
* Late
start to the influenza season in Europe
|
Rare Disease
On a
pro forma basis, Total Revenue from Rare Disease medicines
increased by 4% (10% at CER) in FY 2022 to $7,053m, representing
16% of overall Total Revenue.
Performance
was driven by the durability of the C558 franchise, Soliris and Ultomiris growth in neurology
indications, Ultomiris
gMG launch, and
expansion into new markets.
Strensiq and Koselugo performances were driven by
continued patient demand and geographic expansion.
These
tables show pro forma growth rates for each of the medicines
acquired with Alexion, calculated by comparing FY 2022 revenues
with the medicine's revenues from 1 January 2021 to 31 December
2021.
Soliris
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
3,762
|
|
301
|
2,180
|
805
|
476
|
|
Actual
change6
|
|
(11%)
|
|
(29%)
|
(7%)
|
(21%)
|
11%
|
|
CER
change6
|
|
(5%)
|
|
(10%)
|
(7%)
|
(12%)
|
24%
|
|
Region
|
|
Drivers
and commentary
|
|
US
|
|
Performance
impacted by successful conversion to Ultomiris in PNH59,
aHUS60 and
gMG61,
partially offset by Soliris growth in NMOSD
|
|
Ex-US
|
|
Decline
driven by successful conversion to Ultomiris, slightly offset by growth in NMOSD and expansion
in new markets
|
Ultomiris
|
Total
Revenue
|
|
Worldwide
|
|
Emerging
Markets
|
US
|
Europe
|
Established
RoW
|
|
FY 2022
$m
|
|
1,965
|
|
38
|
1,136
|
481
|
310
|
|
Actual
change6
|
|
34%
|
|
>2x
|
35%
|
49%
|
6%
|
|
CER
change6
|
|
42%
|
|
>2x
|
35%
|
68%
|
26%
|
|
Region
|
|
Drivers
and commentary
|
|
Worldwide
|
|
* Performance
driven by gMG launch in the US and expansion into new
markets
* Quarter-on-quarter variability in revenue growth
can be expected due to Ultomiris every eight-week dosing schedule and lower average
annual treatment cost per patient compared to Soliris
|
|
US
|
|
* Performance driven by successful conversion
from Soliris across PNH, aHUS and gMG
|
|
Europe
|
|
* Growth
driven by strong demand generation following new launch
markets
|
|
Established
RoW
|
|
* Rapid
conversion in new launch markets, strong growth in Japan following
gMG launch
|
Other Rare Disease medicines
|
|
FY
2022
|
%
Change
|
|
|
Total
Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
|
Strensiq
|
|
958
|
16%
|
18%
|
* Performance
driven by strong patient demand and geographic
expansion
|
|
Koselugo
|
|
208
|
93%
|
96%
|
* Growth
driven by expansion in new markets
|
|
Kanuma
|
|
160
|
16%
|
19%
|
* Continued
demand growth in ex-US markets
|
Other medicines (outside the main therapy areas)
|
|
FY
2022
|
%
Change
|
|
|
Total
Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
|
Nexium
|
|
1,367
|
(4%)
|
7%
|
* Nexium (oral) was implemented in China's VBP programme in
February 2021 and Nexium i.v. was implemented in October
2021
* Generic competition in Japan increased in the fourth
quarter
|
|
Others
|
|
381
|
(4%)
|
(1%)
|
|
Financial performance
Table 9: Reported Profit and Loss
|
|
|
FY 2022
|
FY 2021
|
% Change
|
Q4 2022
|
Q4 2021
|
% Change
|
|
||
|
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
|
Total Revenue
|
|
44,351
|
37,417
|
19
|
25
|
11,207
|
12,011
|
(7)
|
1
|
|
|
- Product Sales
|
|
42,998
|
36,541
|
18
|
24
|
10,798
|
11,498
|
(6)
|
2
|
|
|
- Collaboration Revenue
|
|
1,353
|
876
|
54
|
56
|
409
|
513
|
(20)
|
(19)
|
|
|
Cost of
sales
|
|
(12,391)
|
(12,437)
|
-
|
4
|
(2,900)
|
(4,625)
|
(37)
|
(35)
|
|
|
Gross profit
|
|
31,960
|
24,980
|
28
|
35
|
8,307
|
7,386
|
12
|
24
|
|
|
Gross Margin
|
|
71.2%
|
66.0%
|
+5pp
|
+5pp
|
73.1%
|
59.8%
|
+13pp
|
+15pp
|
|
|
Distribution
expense
|
|
(536)
|
(446)
|
20
|
29
|
(156)
|
(124)
|
26
|
38
|
|
|
% Total Revenue
|
|
1.2%
|
1.2%
|
-
|
-
|
1.4%
|
1.0%
|
-
|
-
|
|
|
R&D
expense
|
|
(9,762)
|
(9,736)
|
-
|
5
|
(2,625)
|
(2,584)
|
2
|
9
|
|
|
% Total Revenue
|
|
22.0%
|
26.0%
|
+4pp
|
+4pp
|
23.4%
|
21.5%
|
-2pp
|
-2pp
|
|
|
SG&A
expense
|
|
(18,419)
|
(15,234)
|
21
|
26
|
(4,621)
|
(5,117)
|
(10)
|
(3)
|
|
|
% Total Revenue
|
|
41.5%
|
40.7%
|
-1pp
|
-
|
41.2%
|
42.6%
|
+1pp
|
+2pp
|
|
|
OOI62
& expense
|
|
514
|
1,492
|
(66)
|
(65)
|
189
|
147
|
29
|
33
|
|
|
% Total Revenue
|
|
1.2%
|
4.0%
|
-3pp
|
-3pp
|
1.7%
|
1.2%
|
-
|
-
|
|
|
Operating profit/(loss)
|
|
3,757
|
1,056
|
>3x
|
>3x
|
1,094
|
(292)
|
n/m
|
n/m
|
|
|
Operating Margin
|
|
8.5%
|
2.8%
|
6
|
7
|
9.8%
|
-2.4%
|
+12pp
|
+14pp
|
|
|
Net
finance expense
|
|
(1,251)
|
(1,257)
|
(1)
|
5
|
(315)
|
(335)
|
(6)
|
-
|
|
|
Joint
ventures and associates
|
|
(5)
|
(64)
|
(92)
|
(91)
|
(1)
|
(9)
|
(89)
|
(89)
|
|
|
Profit/(loss) before tax
|
|
2,501
|
(265)
|
n/m
|
n/m
|
778
|
(636)
|
n/m
|
n/m
|
|
|
Taxation
|
|
792
|
380
|
>2x
|
>3x
|
124
|
290
|
(57)
|
21
|
|
|
Tax
rate
|
|
-32%
|
143%
|
|
|
-16%
|
46%
|
|
|
|
|
Profit/(loss) after tax
|
|
3,293
|
115
|
n/m
|
n/m
|
902
|
(346)
|
n/m
|
n/m
|
|
|
Earnings per share
|
|
$ 2.12
|
$0.08
|
n/m
|
n/m
|
$0.58
|
$(0.22)
|
n/m
|
n/m
|
|
Table 10: Reconciliation of Reported Profit before tax to
EBITDA
|
|
|
FY 2022
|
FY 2021
|
% Change
|
Q4 2022
|
Q4 2021
|
% Change
|
||
|
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Reported
Profit/(loss) before tax
|
|
2,501
|
(265)
|
n/m
|
n/m
|
778
|
(636)
|
n/m
|
n/m
|
|
Net
finance expense
|
|
1,251
|
1,257
|
(1)
|
5
|
315
|
335
|
(6)
|
-
|
|
Joint
ventures and associates
|
|
5
|
64
|
(92)
|
(91)
|
1
|
9
|
(89)
|
(89)
|
|
Depreciation,
amortisation and impairment
|
|
5,480
|
6,530
|
(16)
|
(12)
|
1,480
|
2,192
|
(32)
|
(28)
|
|
EBITDA
|
|
9,237
|
7,586
|
22
|
33
|
2,574
|
1,900
|
36
|
56
|
EBITDA
of $9,237m in the year (FY 2021: $7,586m) has been negatively
impacted by the $3,484m (FY 2021: $2,198m) unwind of inventory
fair value uplift recognised on the acquisition of Alexion. EBITDA
of $2,574m in the quarter (Q4 2021: $1,900m) has been negatively
impacted by the $309m (Q4 2021: $1,154m) unwind of inventory fair
value uplift recognised on the acquisition of Alexion. The unwind
of the remaining $114m inventory fair value uplift is expected to
depress EBITDA in 2023.
Table 11: Reconciliation of Reported to Core financial measures: FY
2022
|
FY 2022
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion
|
Other
|
Core
|
Core
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
|
31,960
|
266
|
32
|
3,506
|
(1)
|
35,763
|
28
|
35
|
|
Gross Margin
|
|
71.2%
|
|
|
|
|
80.0%
|
+6pp
|
+6pp
|
|
Distribution
expense
|
|
(536)
|
2
|
-
|
-
|
-
|
(534)
|
20
|
28
|
|
R&D
expense
|
|
(9,762)
|
111
|
124
|
27
|
-
|
(9,500)
|
19
|
24
|
|
SG&A
expense
|
|
(18,419)
|
405
|
4,165
|
38
|
98563
|
(12,826)
|
15
|
21
|
|
Total
operating expense
|
|
(28,717)
|
518
|
4,289
|
65
|
985
|
(22,860)
|
17
|
23
|
|
Other
operating income & expense
|
|
514
|
(67)
|
-
|
-
|
-
|
447
|
(70)
|
(69)
|
|
Operating profit
|
|
3,757
|
717
|
4,321
|
3,571
|
984
|
13,350
|
34
|
42
|
|
Operating Margin
|
|
8.5%
|
|
|
|
|
30.1%
|
+4pp
|
+4pp
|
|
Net
finance expense
|
|
(1,251)
|
-
|
-
|
-
|
277
|
(974)
|
13
|
18
|
|
Taxation
|
|
792
|
(165)
|
(804)
|
(832)
|
(1,049)64
|
(2,058)
|
38
|
46
|
|
EPS
|
|
$2.12
|
$0.36
|
$2.27
|
$1.77
|
$0.14
|
$6.66
|
26
|
33
|
Table 12: Reconciliation of Reported to Core financial measures: Q4
2022
|
Q4 2022
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion
|
Other
|
Core
|
Core
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
|
8,307
|
110
|
8
|
320
|
-
|
8,745
|
(3)
|
6
|
|
Gross Margin
|
|
73.1%
|
|
|
|
|
77.2%
|
+3pp
|
+4pp
|
|
Distribution
Expense
|
|
(156)
|
-
|
-
|
-
|
-
|
(156)
|
27
|
39
|
|
R&D
expense
|
|
(2,625)
|
54
|
41
|
4
|
-
|
(2,526)
|
5
|
12
|
|
SG&A
expense
|
|
(4,621)
|
142
|
1,105
|
3
|
(212)
|
(3,583)
|
6
|
15
|
|
Total
operating expense
|
|
(7,402)
|
196
|
1,146
|
7
|
(212)
|
(6,265)
|
6
|
14
|
|
Other
operating income & expense
|
|
189
|
(59)
|
-
|
-
|
-
|
130
|
(11)
|
(7)
|
|
Operating profit
|
|
1,094
|
247
|
1,154
|
327
|
(212)
|
2,610
|
(21)
|
(10)
|
|
Operating Margin
|
|
9.8%
|
|
|
|
|
23.3%
|
-4pp
|
-3pp
|
|
Net
finance expense
|
|
(315)
|
-
|
-
|
-
|
70
|
(245)
|
5
|
9
|
|
Taxation
|
|
124
|
(72)
|
(223)
|
(84)
|
29
|
(226)
|
(55)
|
(44)
|
|
EPS
|
|
$0.58
|
$0.11
|
$0.60
|
$0.16
|
($0.07)
|
$1.38
|
(17)
|
(5)
|
Profit and Loss drivers
Gross profit
R&D expense
SG&A expense
Other operating income
Net finance expense
-
The
change in Reported and Core Net finance expense in the year was
primarily driven by financing costs on debt for the Alexion
transaction. Reported Net finance expense was also impacted by a
reduction in the discount unwind on acquisition-related
liabilities, including the Diabetes Alliance
Taxation
Dividend per share
Table 13: Cash Flow summary
|
|
|
FY 2022
|
FY 2021
|
Change
|
|
|
|
$m
|
$m
|
$m
|
|
Reported
Operating Profit
|
|
3,757
|
1,056
|
2,701
|
|
Depreciation,
Amortisation and Impairment
|
|
5,480
|
6,530
|
(1,050)
|
|
Decrease
in Working Capital and Short-term Provisions
|
|
3,757
|
2,021
|
1,736
|
|
Gains
on Disposal of Intangible Assets
|
|
(104)
|
(513)
|
409
|
|
Gains
on Disposal of Investments in Associates and Joint
Ventures
|
|
-
|
(776)
|
776
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
|
82
|
14
|
68
|
|
Non-Cash
and Other Movements
|
|
(692)
|
95
|
(787)
|
|
Interest
Paid
|
|
(849)
|
(721)
|
(128)
|
|
Taxation
Paid
|
|
(1,623)
|
(1,743)
|
120
|
|
Net Cash Inflow from Operating Activities
|
|
9,808
|
5,963
|
3,845
|
|
Net Cash Inflow/(Outflow) before Financing Activities
|
|
6,848
|
(5,095)
|
11,943
|
|
Net Cash (Outflow)/Inflow from Financing Activities
|
|
(6,823)
|
3,649
|
(10,472)
|
The
increase in Net Cash Inflow from Operating Activities of $3,845m
primarily reflects an underlying
improvement in business performance, including the contribution
from Alexion for the full year.
The
Reported Operating Profit of $3,757m in the year includes a
negative impact of $3,484m relating to the unwind of the inventory
fair value uplift recognised on the acquisition of Alexion. The
corresponding positive impact of $3,484m in Decrease in Working
Capital and Short-term Provisions offsets the negative impact on
Reported Operating Profit. Overall, the unwind of the fair value
uplift has no impact on Net Cash Inflow from Operating
Activities.
The
change in Working Capital and Short-term Provisions of $1,736m,
whilst being positively impacted by the aforementioned inventory
fair value uplift unwind, has been adversely impacted by the
reduction of Vaxzevria
working capital balances predominantly within Trade and other
payables.
The
change in Non-Cash and Other Movements of ($787m) is primarily
driven by changes in non-current Provisions, as well as increased
foreign exchange volatility on intercompany
transactions.
Capital Expenditure
Capital
Expenditure amounted to $1,091m in the year (FY 2021: $1,091m)
including expenditure relating to Alexion.
Table 14: Net Debt summary
|
|
|
At 31
Dec 2022
|
At 31
Dec 2021
|
|
|
|
$m
|
$m
|
|
Cash
and cash equivalents
|
|
6,166
|
6,329
|
|
Other
investments
|
|
239
|
69
|
|
Cash and investments
|
|
6,405
|
6,398
|
|
Overdrafts
and short-term borrowings
|
|
(350)
|
(387)
|
|
Lease
liabilities
|
|
(953)
|
(987)
|
|
Current
instalments of loans
|
|
(4,964)
|
(1,273)
|
|
Non-current
instalments of loans
|
|
(22,965)
|
(28,134)
|
|
Interest-bearing loans and borrowings (Gross Debt)
|
|
(29,232)
|
(30,781)
|
|
Net
derivatives
|
|
(96)
|
61
|
|
Net Debt
|
|
(22,923)
|
(24,322)
|
Net
Debt decreased by $1,399m in the year to $22,923m. Details of the
committed undrawn bank facilities are disclosed within the going
concern section of Note 1. Details of the Company's solicited
credit ratings are disclosed in Note 3.
Capital allocation
The
Board's aim is to continue to strike a balance between the
interests of the business, financial creditors and the Company's
shareholders. The Company's capital allocation priorities include:
investing in the business and pipeline; maintaining a strong,
investment-grade credit rating; potential value-enhancing business
development opportunities; and supporting the progressive dividend
policy.
In
approving the declaration of dividends, the Board considers both
the liquidity of the company and the level of reserves legally
available for distribution. Dividends are paid to shareholders from
AstraZeneca PLC, a Group holding company with no direct operations.
The ability of AstraZeneca PLC to make shareholder distributions is
dependent on the creation of profits for distribution and the
receipt of funds from subsidiary companies. The consolidated Group
reserves set out in the Condensed consolidated statement of
financial position do not reflect the profit available for
distribution to the shareholders of AstraZeneca PLC.
Summarised financial information for guarantee of securities
of subsidiaries
AstraZeneca
Finance LLC ("AstraZeneca Finance") is the issuer of 0.700% Notes
due 2024, 1.200% Notes due 2026, 1.750% Notes due 2028 and 2.250%
Notes due 2031 (the "AstraZeneca Finance Notes"). Each series of
AstraZeneca Finance Notes has been fully and unconditionally
guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by
AstraZeneca PLC and each of the guarantees by AstraZeneca PLC is
full and unconditional and joint and several.
The
AstraZeneca Finance Notes are senior unsecured obligations of
AstraZeneca Finance and rank equally with all of AstraZeneca
Finance's existing and future senior unsecured and unsubordinated
indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca
Finance Notes is the senior unsecured obligation of AstraZeneca PLC
and ranks equally with all of AstraZeneca PLC's existing and future
senior unsecured and unsubordinated indebtedness. Each guarantee by
AstraZeneca PLC is effectively subordinated to any secured
indebtedness of AstraZeneca PLC to the extent of the value of the
assets securing such indebtedness. The AstraZeneca Finance Notes
are structurally subordinated to indebtedness and other liabilities
of the subsidiaries of AstraZeneca PLC, none of which guarantee the
AstraZeneca Finance Notes.
AstraZeneca
PLC manages substantially all of its operations through divisions,
branches and/or investments in subsidiaries and affiliates.
Accordingly, the ability of AstraZeneca PLC to service its debt and
guarantee obligations is also dependent upon the earnings of its
subsidiaries, affiliates, branches and divisions, whether by
dividends, distributions, loans or otherwise.
Please
refer to the consolidated financial statements of AstraZeneca PLC
in our Annual Report on Form 20-F and reports on Form 6-K with our
quarterly financial results as filed or furnished with the
SEC65 for further financial information
regarding AstraZeneca PLC and its consolidated subsidiaries. For
further details, terms and conditions of the AstraZeneca Finance
Notes please refer to AstraZeneca PLC's Form 6-K furnished to the
SEC on 28 May 2021.
Pursuant
to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities
Act of 1933, as amended (the "Securities Act"), we present below
the summary financial information for AstraZeneca PLC, as
Guarantor, excluding its consolidated subsidiaries, and AstraZeneca
Finance, as the issuer, excluding its consolidated subsidiaries.
The following summary financial information of AstraZeneca PLC and
AstraZeneca Finance is presented on a combined basis and
transactions between the combining entities have been eliminated.
Financial information for non-guarantor entities has been excluded.
Intercompany balances and transactions between the obligor group
and the non-obligor subsidiaries are presented on separate
lines.
Table 15: Obligor group summarised Statement of comprehensive
income
|
|
|
FY 2022
|
|
|
|
$m
|
|
Total
Revenue
|
|
-
|
|
Gross
Profit
|
|
-
|
|
Operating
loss
|
|
(27)
|
|
Loss
for the period
|
|
(687)
|
|
Transactions
with subsidiaries that are not issuers or guarantors
|
|
1,071
|
Table 16: Obligor group summarised Statement of financial
position
|
|
|
At 31 Dec 2022
|
|
|
|
$m
|
|
Current
assets
|
|
4
|
|
Non-current
assets
|
|
-
|
|
Current
liabilities
|
|
(2,839)
|
|
Non-current
liabilities
|
|
(22,797)
|
|
Amounts
due from subsidiaries that are not issuers or
guarantors
|
|
7,806
|
|
Amounts
due to subsidiaries that are not issuers or guarantors
|
|
(293)
|
Foreign exchange
The
Company's transactional currency exposures on working-capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign exchange contracts against
the individual companies' reporting currency. Foreign exchange
gains and losses on forward contracts for transactional hedging are
taken to profit or loss. In addition, the Company's external
dividend payments, paid principally in pounds sterling and Swedish
krona, are fully hedged from announcement to payment
date.
Table 17: Currency sensitivities
The
Company provides the following currency-sensitivity
information:
|
|
|
|
Average spot
rates vs. USD
|
|
Annual impact of 5% strengthening in
FY average rate vs. USD ($m) 66
|
|
Currency
|
Primary Relevance
|
|
FY 202267
|
Jan 202368
|
Change
(%)
|
|
Total Revenue
|
Core Operating Profit
|
|
EUR
|
Total
Revenue
|
|
0.95
|
0.93
|
2
|
|
323
|
159
|
|
CNY
|
Total
Revenue
|
|
6.74
|
6.79
|
(1)
|
|
309
|
174
|
|
JPY
|
Total
Revenue
|
|
131.59
|
130.37
|
1
|
|
181
|
122
|
|
Other69
|
|
|
|
|
|
|
385
|
202
|
|
GBP
|
Operating
expense
|
|
0.81
|
0.82
|
(1)
|
|
46
|
(92)
|
|
SEK
|
Operating
expense
|
|
10.12
|
10.39
|
(3)
|
|
7
|
(55)
|
Sustainability
Since
the last quarterly report, AstraZeneca:
Access to healthcare
Environmental protection
Ethics and transparency
Research and development
This
section covers R&D events and milestones that have occurred
since the prior results announcement on 10 November 2022, up
to and including events on 8 February 2023.
A
comprehensive view of AstraZeneca's pipeline of medicines in human
trials can be found in the latest clinical trials appendix,
available on www.astrazeneca.com/investor-relations.
The clinical trials appendix includes tables with details of the
ongoing clinical trials for AstraZeneca medicines and new molecular
entities in the pipeline.
Oncology
AstraZeneca
presented new data across its diverse portfolio of cancer medicines
at two major medical congresses during the quarter: the 2022 San
Antonio Breast Cancer Symposium (SABCS) and the 64th American
Society of Hematology (ASH), both in December. At SABCS,
AstraZeneca presented 56 abstracts spanning five approved medicines
and seven pipeline medicines with four late-breaking oral
presentations. At ASH, AstraZeneca presented 47 abstracts
showcasing new data across its haematology portfolio and clinical
pipeline.
Significant
new trials that achieved first patient dosed during the period
included:
Tagrisso and
savolitinib
|
Event
|
|
|
Commentary
|
|
Fast
Track Designation
|
US
|
|
Tagrisso in combination with
savolitinib for the treatment of patients with locally advanced or
metastatic NSCLC whose tumours have MET overexpression and/or
amplification, as detected by an FDA-approved test, and who have
had disease progression during or following prior
Tagrisso.
|
Imfinzi and Imjudo (tremelimumab)
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
Imfinzi in combination
with Imjudo plus platinum-based chemotherapy for the treatment
of adult patients with Stage IV NSCLC with no sensitising
EGFR70 mutations
or anaplastic lymphoma kinase. (POSEIDON, November
2022)
|
|
Approval
|
EU
|
|
Imfinzi for the 1st-line
treatment of adult patients with unresectable or metastatic BTC in
combination with chemotherapy. (TOPAZ-1, December
2022)
|
|
Approval
|
JP
|
|
Imfinzi with or without
Imjudo
for the treatment of adult patients
with unresectable HCC. (HIMALAYA, December
2022)
Imfinzi for the treatment of adult patients with curatively
unresectable BTC in combination with chemotherapy. (TOPAZ-1,
December 2022)
Imfinzi for the treatment of
adult patients with unresectable, advanced or recurrent NSCLC in
combination with chemotherapy. (POSEIDON, December
2022)
|
|
Read-out
|
PEARL
Phase III trial
|
|
The PEARL Phase III trial for Imfinzi did not achieve statistical significance for the
primary endpoints of improving overall survival versus
platinum-based chemotherapy as a monotherapy for the treatment of
patients with Stage IV NSCLC whose tumour cells express high levels
(25% or more) of PD-L171, or in a
subgroup of patients at low risk of early mortality. (December
2022)
|
Lynparza
|
Event
|
|
|
Commentary
|
|
Approval
|
EU
|
|
Lynparza in combination with
abiraterone for the treatment of mCRPC in adult men for whom
chemotherapy is not clinically indicated. (PROpel, December
2022)
|
|
PDUFA72
date change
|
US
|
|
The FDA indicated it will extend the PDUFA date by three months to
March 2023 in order to provide further time for a full review of
the sNDA73 for
Lynparza
in combination with abiraterone for
the treatment of mCRPC. (PROpel, December 2022)
|
Calquence
|
Event
|
|
|
Commentary
|
|
Presentation:
ASH
|
Real-world
evidence and long-term follow-up data
|
|
Real-world evidence and long-term follow-up data support consistent
efficacy and safety profile of Calquence.
|
|
Approval
|
JP
|
|
Calquence for the treatment of
adult patients with treatment-naïve chronic lymphocytic
leukaemia (ELEVATE-TN)
|
|
CHMP
positive opinion
|
EU
|
|
Maleate tablet formulation
|
Enhertu
|
Event
|
|
|
Commentary
|
|
Presentation:
SABCS
|
DESTINY-Breast03
Phase III trial
|
|
Updated OS74 results
from the DESTINY-Breast03 Phase III trial, presented at SABCS 2022,
demonstrated Enhertu statistically significant and clinically
meaningful improvement in OS compared to T-DM175 in
patients with HER2-positive unresectable and/or metastatic breast
cancer.
|
|
|
DESTINY-Breast02
Phase III trial
|
|
Primary results from the DESTINY-Breast02 Phase III trial
demonstrated clinical benefit of Enhertu compared to conventional chemotherapy-based
regimens in patients with HER2-positive metastatic breast cancer
previously treated with T-DM1.
|
|
Approval
|
EU
|
|
Enhertu for patients with
advanced HER2-positive gastric or gastroesophageal junction
adenocarcinoma who have received prior trastuzumab-based regimen,
based on DESTINY-Gastric02 and DESTINY-Gastric01 trials. (December
2022)
|
Datopotamab deruxtecan (Dato-DXd)
|
Event
|
|
|
Commentary
|
|
Presentation:
SABCS
|
TROPION-PanTumor01
Phase I trial
|
|
Initial results from the TROPION-PanTumor01 Phase I trial showed
encouraging and durable efficacy of Dato-DXd in patients with
heavily pre-treated HR-positive, HER2-low or HER2-negative
unresectable or metastatic breast cancer. In this cohort, Dato-DXd
demonstrated an objective response rate of 27% as assessed by
blinded independent central review. All responses were partial and
56% of patients achieved stable disease. The disease control rate
was 85% and median PFS was 8.3 months.
Updated results from the TROPION-PanTumor01 Phase I trial
demonstrated Dato-DXd continued to demonstrate encouraging
responses in patients with heavily pretreated metastatic TNBC and
disease progression following standard treatment.
In the TNBC cohort, Dato-DXd demonstrated an ORR76 of 32%
including one complete response, 13 partial responses and 18 cases
of stable disease as assessed by blinded independent central
review. In the overall cohort, Dato-DXd demonstrated median PFS of
4.4 months and median OS of 13.5 months. (December
2022)
|
Camizestrant
|
Event
|
|
|
Commentary
|
|
Presentation: SABCS
|
SERENA-2 Phase II trial
|
|
Detailed results from the SERENA-2 Phase II trial of camizestrant,
AstraZeneca's next-generation oral selective oestrogen receptor
degrader, were presented at SABCS 2022 and demonstrated
statistically significant and clinically meaningful improvement in
PFS at both 75mg and 150mg dose levels versus Faslodex (fulvestrant) in post-menopausal patients with
ER-positive locally advanced or metastatic breast cancer,
previously treated with endocrine therapy for advanced
disease.
In the overall population, camizestrant significantly reduced risk
of disease progression or death by 42% at a 75mg dose (based on HR
of 0.58, 90% confidence interval) and mPFS of 7.2 versus 3.7 months
and 33% at a 150mg dose (based on HR of 0.67, 90% confidence
interval) and mPFS of 7.7 versus 3.7 months compared to
Faslodex, the current SERD standard of
care.
|
Capivasertib
|
Event
|
|
|
Commentary
|
|
Presentation:
SABCS
|
CAPItello-291
Phase III trial
|
|
Detailed results from the CAPItello-291 Phase III trial of
capivasertib in combination with Faslodex demonstrated a statistically significant and
clinically meaningful improvement in PFS versus placebo plus
Faslodex
in patients with HR-positive, HER2-low
or negative, locally advanced or metastatic breast cancer following
recurrence or progression on, or after, endocrine therapy (with or
without a CDK4/6 inhibitor).
Capivasertib in combination with Faslodex demonstrated a 40% reduction in the risk of
disease progression or death versus placebo plus
Faslodex
in the overall trial population (based
on a HR of 0.60, 95% confidence interval) and median PFS 7.2 versus
3.6 months. In the AKT pathway biomarker-altered population, which
affects up to 50% of patients with advanced HR-positive breast
cancer, capivasertib plus Faslodex reduced risk of disease progression or death by
50% versus placebo plus Faslodex.
|
BioPharmaceuticals - CVRM
Farxiga
|
Event
|
|
|
Commentary
|
|
Approval
|
EU
|
|
Forxiga for heart failure with
reduced ejection fraction to cover patients across the full
spectrum of left ventricular ejection fraction including heart
failure with mildly reduced and preserved ejection fraction.
(DELIVER, February 2023)
|
BioPharmaceuticals - R&I
Significant
new trials in R&I initiated since the previous results
included:
TILIA,
a Phase III trial for tozorakimab in acute respiratory failure in
patients with viral lung infection
Tezspire
|
Event
|
|
|
Commentary
|
|
Approval
|
US,
EU
|
|
The Tezspire pre-filled pen for self-administration in a
pre-filled, single-use pen for patients aged 12 years and older
with severe asthma. (January, February 2023)
|
Airsupra
(PT027)
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
Airsupra for the as-needed
treatment or prevention of bronchoconstriction and to reduce the
risk of exacerbations in people with asthma aged 18 years and
older. This is the first approval for Airsupra, formerly known as PT027. (January
2023)
|
Saphnelo
|
Event
|
|
|
Commentary
|
|
Orphan
Drug Designation
|
US
|
|
Saphnelo for idiopathic
inflammatory myopathies (including myositis), a group of diseases
in which type I interferon plays a key role. (December
2022)
|
Fasenra
|
Event
|
|
|
Commentary
|
|
Phase
III trial discontinued
|
HUDSON
|
|
Eosinophilic gastritis (EG/EGE) trial discontinued due to strategic
portfolio prioritisation. This discontinuation was not related to
any safety or efficacy findings. (January 2023)
|
Tozorakimab
|
Event
|
|
|
Commentary
|
|
Fast
Track Designation
|
US
|
|
Tozorakimab to reduce the risk of invasive mechanical ventilation,
extracorporeal membrane oxygenation or death (acute respiratory
failure) in adults hospitalised with viral lung infection and
requiring supplemental oxygen. (December)
|
BioPharmaceuticals - V&I
A
significant new trial commenced in the period:
SUPERNOVA
was originally planned to evaluate a combination of AZD3152 and
cilgavimab, one of the two monoclonal antibodies that make up
Evusheld. In January 2023,
the decision was taken to investigate AZD3152 alone, which has been
shown to neutralise all known variants to date. AstraZeneca is
aiming to make AZD3152 available as a new option for COVID-19 in
the second half of 2023, subject to trial readouts and regulatory
reviews.
In
February 2023, AstraZeneca reached agreement with the U.S.
Department of Defense's Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense
(JPEO-CBRND), in collaboration with the U.S. Department of Health
and Human Services' Biomedical Advanced Research and Development
Authority (BARDA), part of the Administration for Strategic
Preparedness and Response within the U.S. Department of Health and
Human Services, via the Medical CBRN Defense Consortium (MCDC)
Other Transaction Agreement (OTA) to develop an RNA-based universal
pandemic influenza prototype vaccine. As part of the resulting
prototype project, AstraZeneca could receive up to approximately
$80m over three years to develop the vaccine from preclinical
research through a Phase I/II clinical study.
Evusheld
|
Event
|
|
|
Commentary
|
|
Revision
to Emergency Use Authorisation
|
US
|
|
The FDA has revised Evusheld's Emergency Use Authorisation to limit the use
of Evusheld to when the combined frequency of non-susceptible
SARS-CoV-2 variants nationally in the US is ≤90%. (January
2023)
Evusheld is not currently
authorised by the US FDA for pre-exposure prophylaxis of COVID-19
(as of January 2023), due to sustained high frequency of
circulating SARS-CoV-2 variants against which Evusheld does not retain in vitro neutralisation.
|
Beyfortus
|
Event
|
|
|
Commentary
|
|
Regulatory
submission
|
US
|
|
Nirsevimab for prevention of lower respiratory tract disease in
newborns and infants entering or during their first RSV season, and
for children up to 24 months of age who remain vulnerable to severe
RSV disease through their second RSV season. (January
2023)
The FDA has indicated it will work to expedite its review. The
PDUFA date is in the third quarter of 2023.
|
Rare Disease
A
significant new trial achieved first patient dosed during the
period:
Vemircopan (ALXN2050)
|
Event
|
|
|
Commentary
|
|
Conference:
ASH
|
PNH
monotherapy Phase II trial
|
|
An oral presentation detailing interim results from a Phase II
open-label trial of vemircopan (ALXN2050) highlighted efficacy and
safety data from the treatment-naïve patient group,
establishing proof-of-concept as a monotherapy for
PNH.
Vemircopan monotherapy controlled IVH as demonstrated by reduction
in LDH to <1.5xULN and prevented clinically significant EVH,
demonstrated by 3.9 g/dL increase in Hgb level and ARC
reduction.
|
Condensed Consolidated Financial Statements
Table 18: Condensed consolidated statement of comprehensive income:
FY 2022
|
For the
year ended 31
December
|
|
2022
|
2021
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
44,351
|
37,417
|
|
Product Sales
|
|
42,998
|
36,541
|
|
Collaboration Revenue
|
|
1,353
|
876
|
|
Cost of
sales
|
|
(12,391)
|
(12,437)
|
|
Gross profit
|
|
31,960
|
24,980
|
|
Distribution
expense
|
|
(536)
|
(446)
|
|
Research
and development expense
|
|
(9,762)
|
(9,736)
|
|
Selling,
general and administrative expense
|
|
(18,419)
|
(15,234)
|
|
Other
operating income and expense
|
|
514
|
1,492
|
|
Operating profit
|
|
3,757
|
1,056
|
|
Finance
income
|
|
95
|
43
|
|
Finance
expense
|
|
(1,346)
|
(1,300)
|
|
Share
of after tax losses in associates and joint ventures
|
|
(5)
|
(64)
|
|
Profit/(loss) before tax
|
|
2,501
|
(265)
|
|
Taxation
|
|
792
|
380
|
|
Profit for the period
|
|
3,293
|
115
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
1,118
|
626
|
|
Net
losses on equity investments measured at fair value through other
comprehensive income
|
|
(88)
|
(187)
|
|
Fair
value movements related to own credit risk on bonds designated as
fair value through profit or loss
|
|
2
|
-
|
|
Tax on
items that will not be reclassified to profit or loss
|
|
(216)
|
105
|
|
|
|
816
|
544
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
(1,446)
|
(483)
|
|
Foreign
exchange arising on designated liabilities in net investment
hedges
|
|
(282)
|
(321)
|
|
Fair
value movements on cash flow hedges
|
|
(97)
|
(167)
|
|
Fair
value movements on cash flow hedges transferred to profit and
loss
|
|
73
|
208
|
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
(8)
|
34
|
|
Costs
of hedging
|
|
(7)
|
(6)
|
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
73
|
46
|
|
|
|
(1,694)
|
(689)
|
|
Other comprehensive loss, net of tax
|
|
(878)
|
(145)
|
|
Total comprehensive income/(loss) for the period
|
|
2,415
|
(30)
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
3,288
|
112
|
|
Non-controlling
interests
|
|
5
|
3
|
|
|
|
3,293
|
115
|
|
Total comprehensive income/(loss) attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
2,413
|
(33)
|
|
Non-controlling
interests
|
|
2
|
3
|
|
|
|
2,415
|
(30)
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$2.12
|
$0.08
|
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$2.11
|
$0.08
|
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,548
|
1,418
|
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,560
|
1,427
|
Table 19: Condensed consolidated statement of comprehensive income:
Q4 2022
|
For the
quarter ended 31
December
|
|
2022
|
2021
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
11,207
|
12,011
|
|
Product Sales
|
|
10,798
|
11,498
|
|
Collaboration Revenue
|
|
409
|
513
|
|
Cost of
sales
|
|
(2,900)
|
(4,625)
|
|
Gross profit
|
|
8,307
|
7,386
|
|
Distribution
expense
|
|
(156)
|
(124)
|
|
Research
and development expense
|
|
(2,625)
|
(2,584)
|
|
Selling,
general and administrative expense
|
|
(4,621)
|
(5,117)
|
|
Other
operating income and expense
|
|
189
|
147
|
|
Operating profit/(loss)
|
|
1,094
|
(292)
|
|
Finance
income
|
|
45
|
1
|
|
Finance
expense
|
|
(360)
|
(336)
|
|
Share
of after tax losses in associates and joint ventures
|
|
(1)
|
(9)
|
|
Profit/(loss) before tax
|
|
778
|
(636)
|
|
Taxation
|
|
124
|
290
|
|
Profit/(loss) for the period
|
|
902
|
(346)
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
(165)
|
34
|
|
Net
losses on equity investments measured at fair value through other
comprehensive income
|
|
(67)
|
(331)
|
|
Fair
value movements related to own credit risk on bonds designated as
fair value through profit or loss
|
|
1
|
(4)
|
|
Tax on
items that will not be reclassified to profit or loss
|
|
75
|
34
|
|
|
|
(156)
|
(267)
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
1,047
|
(115)
|
|
Foreign
exchange arising on designated liabilities in net investment
hedges
|
|
39
|
(46)
|
|
Fair
value movements on cash flow hedges
|
|
117
|
(64)
|
|
Fair
value movements on cash flow hedges transferred to profit and
loss
|
|
(177)
|
71
|
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
(41)
|
12
|
|
Costs
of hedging
|
|
4
|
-
|
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
(22)
|
9
|
|
|
|
967
|
(133)
|
|
Other comprehensive income/(loss), net of tax
|
|
811
|
(400)
|
|
Total comprehensive income/(loss) for the period
|
|
1,713
|
(746)
|
|
Profit/(loss) attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
901
|
(347)
|
|
Non-controlling
interests
|
|
1
|
1
|
|
|
|
902
|
(346)
|
|
Total comprehensive income/(loss) attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,712
|
(747)
|
|
Non-controlling
interests
|
|
1
|
1
|
|
|
|
1,713
|
(746)
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$0.58
|
$(0.22)
|
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$0.58
|
$(0.22)
|
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,549
|
1,547
|
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,559
|
1,547
|
Table 20: Condensed consolidated statement of financial
position
|
|
|
At 31 Dec
2022
|
At 31 Dec
2021
|
|
|
|
$m
|
$m
|
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
|
8,507
|
9,183
|
|
Right-of-use
assets
|
|
942
|
988
|
|
Goodwill
|
|
19,820
|
19,997
|
|
Intangible
assets
|
|
39,307
|
42,387
|
|
Investments
in associates and joint ventures
|
|
76
|
69
|
|
Other
investments
|
|
1,066
|
1,168
|
|
Derivative
financial instruments
|
|
74
|
102
|
|
Other
receivables
|
|
835
|
895
|
|
Deferred
tax assets
|
|
3,263
|
4,330
|
|
|
|
73,890
|
79,119
|
|
Current assets
|
|
|
|
|
Inventories
|
|
4,699
|
8,983
|
|
Trade
and other receivables
|
|
10,521
|
9,644
|
|
Other
investments
|
|
239
|
69
|
|
Derivative
financial instruments
|
|
87
|
83
|
|
Intangible
assets
|
|
-
|
105
|
|
Income
tax receivable
|
|
731
|
663
|
|
Cash
and cash equivalents
|
|
6,166
|
6,329
|
|
Assets
held for sale
|
|
150
|
368
|
|
|
|
22,593
|
26,244
|
|
Total assets
|
|
96,483
|
105,363
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(5,314)
|
(1,660)
|
|
Lease
liabilities
|
|
(228)
|
(233)
|
|
Trade
and other payables
|
|
(19,040)
|
(18,938)
|
|
Derivative
financial instruments
|
|
(93)
|
(79)
|
|
Provisions
|
|
(722)
|
(768)
|
|
Income
tax payable
|
|
(896)
|
(916)
|
|
|
|
(26,293)
|
(22,594)
|
|
Non-current liabilities
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(22,965)
|
(28,134)
|
|
Lease
liabilities
|
|
(725)
|
(754)
|
|
Derivative
financial instruments
|
|
(164)
|
(45)
|
|
Deferred
tax liabilities
|
|
(2,944)
|
(6,206)
|
|
Retirement
benefit obligations
|
|
(1,168)
|
(2,454)
|
|
Provisions
|
|
(896)
|
(956)
|
|
Other
payables
|
|
(4,270)
|
(4,933)
|
|
|
|
(33,132)
|
(43,482)
|
|
Total liabilities
|
|
(59,425)
|
(66,076)
|
|
Net assets
|
|
37,058
|
39,287
|
|
Equity
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
Share
capital
|
|
387
|
387
|
|
Share
premium account
|
|
35,155
|
35,126
|
|
Other
reserves
|
|
2,069
|
2,045
|
|
Retained
earnings
|
|
(574)
|
1,710
|
|
|
|
37,037
|
39,268
|
|
Non-controlling
interests
|
|
21
|
19
|
|
Total equity
|
|
37,058
|
39,287
|
Table 21: Condensed consolidated statement of changes in
equity
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 Jan 2021
|
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
|
Profit
for the period
|
|
-
|
-
|
-
|
112
|
112
|
3
|
115
|
|
Other
comprehensive loss
|
|
-
|
-
|
-
|
(145)
|
(145)
|
-
|
(145)
|
|
Transfer
to other reserves
|
|
-
|
-
|
21
|
(21)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,882)
|
(3,882)
|
-
|
(3,882)
|
|
Issue
of Ordinary Shares
|
|
59
|
27,155
|
-
|
-
|
27,214
|
-
|
27,214
|
|
Share-based
payments charge for the period
|
|
-
|
-
|
-
|
615
|
615
|
-
|
615
|
|
Settlement
of share plan awards
|
|
-
|
-
|
-
|
(781)
|
(781)
|
-
|
(781)
|
|
Issue
of replacement Alexion share awards upon acquisition
|
|
-
|
-
|
-
|
513
|
513
|
-
|
513
|
|
Net
movement
|
|
59
|
27,155
|
21
|
(3,589)
|
23,646
|
3
|
23,649
|
|
At 31 Dec 2021
|
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
|
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2022
|
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
|
Profit
for the period
|
|
-
|
-
|
-
|
3,288
|
3,288
|
5
|
3,293
|
|
Other
comprehensive loss
|
|
-
|
-
|
-
|
(875)
|
(875)
|
(3)
|
(878)
|
|
Transfer
to other reserves
|
|
-
|
-
|
24
|
(24)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(4,485)
|
(4,485)
|
-
|
(4,485)
|
|
Issue
of Ordinary Shares
|
|
-
|
29
|
-
|
-
|
29
|
-
|
29
|
|
Share-based
payments charge for the period
|
|
-
|
-
|
-
|
619
|
619
|
-
|
619
|
|
Settlement
of share plan awards
|
|
-
|
-
|
-
|
(807)
|
(807)
|
-
|
(807)
|
|
Net
movement
|
|
-
|
29
|
24
|
(2,284)
|
(2,231)
|
2
|
(2,229)
|
|
At 31 Dec 2022
|
|
387
|
35,155
|
2,069
|
(574)
|
37,037
|
21
|
37,058
|
Table 22: Condensed consolidated statement of cash
flows
|
For the
year ended 31
December
|
|
2022
|
2021
|
|
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
|
|
Profit/(loss)
before tax
|
|
2,501
|
(265)
|
|
Finance
income and expense
|
|
1,251
|
1,257
|
|
Share
of after tax losses of associates and joint ventures
|
|
5
|
64
|
|
Depreciation,
amortisation and impairment
|
|
5,480
|
6,530
|
|
Increase
in trade and other receivables
|
|
(1,349)
|
(961)
|
|
Decrease
in inventories
|
|
3,941
|
1,577
|
|
Increase
in trade and other payables and provisions
|
|
1,165
|
1,405
|
|
Gains
on disposal of intangible assets
|
|
(104)
|
(513)
|
|
Gains
on disposal of investments in associates and joint
ventures
|
|
-
|
(776)
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
|
82
|
14
|
|
Non-cash and other
movements
|
|
(692)
|
95
|
|
Cash generated from operations
|
|
12,280
|
8,427
|
|
Interest
paid
|
|
(849)
|
(721)
|
|
Tax
paid
|
|
(1,623)
|
(1,743)
|
|
Net cash inflow from operating activities
|
|
9,808
|
5,963
|
|
Cash flows from investing activities
|
|
|
|
|
Acquisition
of subsidiaries, net of cash acquired
|
|
(48)
|
(9,263)
|
|
Payments
upon vesting of employee share awards attributable to business
combinations
|
|
(215)
|
(211)
|
|
Payment
of contingent consideration from business combinations
|
|
(772)
|
(643)
|
|
Purchase
of property, plant and equipment
|
|
(1,091)
|
(1,091)
|
|
Disposal
of property, plant and equipment
|
|
282
|
13
|
|
Purchase
of intangible assets
|
|
(1,480)
|
(1,109)
|
|
Disposal
of intangible assets and assets held for sale
|
|
447
|
587
|
|
Movement
in profit-participation liability
|
|
-
|
20
|
|
Purchase
of non-current asset investments
|
|
(45)
|
(184)
|
|
Disposal
of non-current asset investments
|
|
42
|
9
|
|
Movement
in short-term investments, fixed deposits and other investing
instruments
|
|
(114)
|
96
|
|
Payments
to associates and joint ventures
|
|
(26)
|
(92)
|
|
Disposal
of investments in associates and joint ventures
|
|
-
|
776
|
|
Interest
received
|
|
60
|
34
|
|
Net cash outflow from investing activities
|
|
(2,960)
|
(11,058)
|
|
Net cash inflow/(outflow) before financing activities
|
|
6,848
|
(5,095)
|
|
Cash flows from financing activities
|
|
|
|
|
Proceeds
from issue of share capital
|
|
29
|
29
|
|
Issue
of loans and borrowings
|
|
-
|
12,929
|
|
Repayment
of loans and borrowings
|
|
(1,271)
|
(4,759)
|
|
Dividends
paid
|
|
(4,364)
|
(3,856)
|
|
Hedge
contracts relating to dividend payments
|
|
(127)
|
(29)
|
|
Repayment
of obligations under leases
|
|
(244)
|
(240)
|
|
Movement
in short-term borrowings
|
|
74
|
(276)
|
|
Payments
to acquire non-controlling interests
|
|
-
|
(149)
|
|
Payment
of Acerta Pharma share purchase liability
|
|
(920)
|
-
|
|
Net cash (outflow)/inflow from financing activities
|
|
(6,823)
|
3,649
|
|
Net
increase/(decrease) in Cash and cash equivalents in the
period
|
|
25
|
(1,446)
|
|
Cash
and cash equivalents at the beginning of the period
|
|
6,038
|
7,546
|
|
Exchange
rate effects
|
|
(80)
|
(62)
|
|
Cash and cash equivalents at the end of the period
|
|
5,983
|
6,038
|
|
Cash and cash equivalents consist of:
|
|
|
|
|
Cash
and cash equivalents
|
|
6,166
|
6,329
|
|
Overdrafts
|
|
(183)
|
(291)
|
|
|
|
5,983
|
6,038
|
Notes to the Condensed Consolidated Financial
Statements
Note 1: Basis of preparation and accounting policies
The
Condensed Consolidated Financial Statements for the year ended 31
December 2022 have been prepared in accordance with UK-adopted
International Accounting Standards and with the requirements of the
Companies Act 2006 as applicable to companies reporting under those
standards. The Condensed Consolidated Financial Statements also
comply fully with International Financial Reporting Standards
(IFRSs) as issued by the International Accounting Standards Board
(IASB) and International Accounting Standards as adopted by the
European Union.
The
Condensed Consolidated Financial Statements for the year ended 31
December 2022 include Alexion's results for the period. Alexion's
post-acquisition results for 2021 were consolidated into the
Group's results from 21 July 2021 therefore the respective
comparative periods shown are not entirely comparable with the
current period.
These
Condensed Consolidated Financial Statements comprise the financial
results of AstraZeneca PLC for the years to 31 December 2022 and
2021 together with the Statement of financial position as at 31
December 2022 and 2021. The results for the year to 31 December
2022 have been extracted from the 31 December 2022 audited
Consolidated Financial Statements which have been approved by the
Board of Directors. These have not yet been delivered to the
Registrar of Companies but are expected to be published on 21
February 2023 within the Annual Report and Form 20-F Information
2022.
The
financial information set out above does not constitute the Group's
statutory accounts for the years to 31 December 2022 or 2021 but is
derived from those accounts. The auditors have reported on those
accounts: their reports (i) were unqualified, (ii) did not include
a reference to any matters to which the auditors drew attention by
way of emphasis without qualifying their report and (iii) did not
contain a statement under section 498 (2) or (3) of the Companies
Act 2006 in respect of the accounts for the year to 31 December
2022 or 31 December 2021. Statutory accounts for the year to 31
December 2022 were approved by the Board of Directors for release
on 9 February 2023.
The
Condensed Consolidated Financial Statements have been prepared
applying the accounting policies that were applied in the
preparation of the Group's published consolidated financial
statements for the year ended 31 December 2021.
AstraZeneca
has assessed the impact of the uncertainty presented by the
COVID-19 pandemic and the Russia-Ukraine conflict on the Financial
Statements, specifically considering the impact on key judgements
and significant estimates along with several other areas of
increased risk. No material accounting impacts relating to COVID-19
or the Russia-Ukraine conflict were recognised in the
year.
Going concern
The
Group has considerable financial resources available. As at 31
December 2022, the Group has $11.1bn in financial resources (Cash
and cash equivalent balances of $6.2bn and undrawn committed bank
facilities of $4.9bn available until April 2026 with only $5.5bn of
borrowings due within one year). All facilities contain no
financial covenants and were undrawn at 31 December 2022.
On 2 February 2023, the Group entered
into an additional $2.0bn of two-year committed bank
facilities.
The
Group's revenues are largely derived from sales of medicines
covered by patents. which provide a relatively high level of
resilience and predictability to cash inflows, although government
price interventions in response to budgetary constraints are
expected to continue to adversely affect revenues in some of our
significant markets. The Group, however, anticipates new revenue
streams from both recently launched medicines and those in
development, and the Group has a wide diversity of customers and
suppliers across different geographic areas.
Consequently,
the Directors believe that, overall, the Group is well placed to
manage its business risks successfully. Accordingly, they continue
to adopt the going concern basis in preparing the Condensed
Consolidated Financial Statements.
Legal proceedings
The
information contained in Note 6 updates the disclosures concerning
legal proceedings and contingent liabilities in the Group's
Annual
Report and Form 20-F Information 2021.
Note 2: Intangible assets
In
accordance with IAS 36 'Impairment of Assets', reviews for triggers
of impairment or impairment reversals at an individual asset or
cash generating unit level were conducted, and impairment tests
carried out where triggers were identified. As a result, total net
impairment charges of $224m have been recorded against intangible
assets during the year ended 31 December 2022 (FY 2021: $2,085m net
charge). Net impairment charges in respect of medicines in
development and launched medicines were $95m (FY 2021: $1,464m) and
$146m (FY 2021: $603m charge) respectively.
Note 3: Net Debt
The
table below provides an analysis of Net Debt and a reconciliation
of Net Cash Flow to the movement in Net Debt. The Group monitors
Net Debt as part of its capital-management policy as described in
Note 28 of the Annual Report and Form
20-F Information 2021. Net Debt is a non-GAAP financial
measure.
Table 23: Net Debt
|
|
|
At 1 Jan 2022
|
Cash flow
|
Acquisitions
|
Non-cash & other
|
Exchange movements
|
At 31 Dec 2022
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current
instalments of loans
|
|
(28,134)
|
-
|
(2)
|
4,957
|
214
|
(22,965)
|
|
Non-current
instalments of leases
|
|
(754)
|
-
|
(3)
|
(2)
|
34
|
(725)
|
|
Total long-term debt
|
|
(28,888)
|
-
|
(5)
|
4,955
|
248
|
(23,690)
|
|
Current
instalments of loans
|
|
(1,273)
|
1,271
|
(3)
|
(4,959)
|
-
|
(4,964)
|
|
Current
instalments of leases
|
|
(233)
|
253
|
(1)
|
(260)
|
13
|
(228)
|
|
Bank
collateral received
|
|
(93)
|
4
|
-
|
-
|
-
|
(89)
|
|
Other
short-term borrowings excluding overdrafts
|
|
(3)
|
(78)
|
-
|
-
|
3
|
(78)
|
|
Overdrafts
|
|
(291)
|
85
|
-
|
-
|
23
|
(183)
|
|
Total current debt
|
|
(1,893)
|
1,535
|
(4)
|
(5,219)
|
39
|
(5,542)
|
|
Gross borrowings
|
|
(30,781)
|
1,535
|
(9)
|
(264)
|
287
|
(29,232)
|
|
Net
derivative financial instruments
|
|
61
|
73
|
-
|
(230)
|
-
|
(96)
|
|
Net borrowings
|
|
(30,720)
|
1,608
|
(9)
|
(494)
|
287
|
(29,328)
|
|
Cash
and cash equivalents
|
|
6,329
|
(72)
|
12
|
-
|
(103)
|
6,166
|
|
Other
investments - current
|
|
69
|
168
|
8
|
-
|
(6)
|
239
|
|
Cash and investments
|
|
6,398
|
96
|
20
|
-
|
(109)
|
6,405
|
|
Net Debt
|
|
(24,322)
|
1,704
|
11
|
(494)
|
178
|
(22,923)
|
Non-cash
movements in the period include fair value adjustments under IFRS 9
Financial Instruments.
The
Group has agreements with some bank counterparties whereby the
parties agree to post cash collateral on financial derivatives, for
the benefit of the other, equivalent to the market valuation of the
derivative positions above a predetermined threshold. The carrying
value of such cash collateral held by the Group at 31 December 2022
was $89m (31 December 2021: $93m) and the carrying value of such
cash collateral posted by the Group at 31 December 2022 was $162m
(31 December 2021: $47m). Cash collateral pledged to counterparties
is recognised as a financial asset and is included in Other
investments - current as at 31 December 2022. In prior years, cash
collateral pledged to counterparties was included in Cash and cash
equivalents.
The
equivalent GAAP measure to Net Debt is 'liabilities arising from
financing activities', which excludes the amounts for cash and
overdrafts, other investments and non-financing derivatives shown
above and includes the Acerta Pharma share purchase liability of
$1,646m (31 December 2021: $2,458m), $867m of which is shown in
current other payables and $779m is shown in non-current other
payables.
Net
Debt decreased by $1,399m in the year to $22,923m. Details of the
committed undrawn bank facilities are disclosed within the going
concern section of Note 1.
During
the year ended 31 December 2022, Standard and Poor's upgraded the
Company's solicited credit ratings to long term: A; and short term:
A-1. There were no changes to Moody's solicited credit ratings
(long term: A3; short term: P-2).
Note 4: Financial Instruments
As
detailed in the Group's most recent annual financial statements,
the principal financial instruments consist of derivative financial
instruments, other investments, trade and other receivables, cash
and cash equivalents, trade and other payables, lease liabilities
and interest-bearing loans and borrowings.
The
Group has certain equity investments that are categorised as Level
3 in the fair value hierarchy that are held at $186m at 31 December
2022 (31 December 2021: $104m) and for which fair value gains of
$50m (FY 2021: $nil) have been recognised in the year ended 31
December 2022. In the absence of specific market data, these
unlisted investments are held at fair value based on the cost of
investment and adjusting as necessary for impairments and
revaluations on new funding rounds, which are seen to approximate
the fair value. All other fair value gains and/or losses that are
presented in Net losses on equity investments measured at fair
value through other comprehensive income in the Condensed
consolidated statement of comprehensive income for the year ended
31 December 2022 are Level 1 fair value measurements, valued based
on quoted prices in active markets.
Financial
instruments measured at fair value include $1,079m of other
investments, $4,486m held in money-market funds, $294m of loans
designated at fair value through profit or loss and ($96m) of
derivatives as at 31 December 2022. With the exception of
derivatives being Level 2 fair valued, certain equity investments
as described above and an equity warrant of $19m categorised as
Level 3, the aforementioned balances are Level 1 fair valued.
Financial instruments measured at amortised cost include $64m of
fixed deposits and $162m of cash collateral pledged to
counterparties. The total fair value of interest-bearing loans and
borrowings at 31 December 2022, which have a carrying value of
$29,232m in the Condensed consolidated statement of financial
position, was $27,898m.
Table 24: Financial instruments - contingent
consideration
|
|
|
2022
|
2021
|
|
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
|
2,544
|
321
|
2,865
|
3,323
|
|
Settlements
|
|
(763)
|
(9)
|
(772)
|
(643)
|
|
Disposals
|
|
-
|
(121)
|
(121)
|
-
|
|
Revaluations
|
|
182
|
(100)
|
82
|
14
|
|
Reclass
to other payables
|
|
-
|
-
|
-
|
(55)
|
|
Discount
unwind
|
|
161
|
7
|
168
|
226
|
|
At 31 December
|
|
2,124
|
98
|
2,222
|
2,865
|
Contingent
consideration arising from business combinations is fair valued
using decision-tree analysis, with key inputs including the
probability of success, consideration of potential delays and the
expected levels of future revenues.
The
contingent consideration balance relating to BMS's share of the
global diabetes alliance of $2,124m (31 December 2021:
$2,544m) would increase/decrease by $212m with an increase/decrease
in sales of 10%, as compared with the current
estimates.
Note 5: Pensions and other post-retirement benefit
obligations
The net
pensions and other post-retirement benefit obligations position, as
recorded under IAS 19 Employee Benefits, at 31 December 2022 was a
liability of $1,078m (31 December 2021: $2,454m liability). Pension
schemes in a net surplus position at 31 December 2022 totalled $90m
and are recorded within Other receivables in non-current assets.
Pension schemes in a net deficit position at 31 December 2022
totalled $1,168m (31 December 2021: $2,454m) and are recorded
within Retirement benefit obligations in non-current
liabilities.
The
decrease in the net liability of $1,376m is driven by actuarial
gains of $1,118m that have been reflected within the Condensed
consolidated statement of comprehensive income.
Changes
in actuarial assumptions, primarily movements in discount rates,
led to an actuarial gain on scheme obligations in the year of
$3,585m (gains in UK, Sweden, US and RoW liabilities of $2,243m,
$806m, $268m and $268m respectively), which reflected increases in
corporate bond yields. These movements were partially offset by
actuarial losses on the pension fund asset values in the year of
$2,467m (losses in UK, Sweden, US and ROW assets of $1,964m, $153m,
$295m and $55m respectively).
Note 6: Legal proceedings and contingent liabilities
AstraZeneca
is involved in various legal proceedings considered typical to its
business, including litigation and investigations, including
Government investigations, relating to product liability,
commercial disputes, infringement of intellectual property (IP)
rights, the validity of certain patents, anti-trust law and sales
and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures
concerning legal proceedings in the Company's Annual Report and
Form 20-F Information 2021, H1 2022 and Q3 2022 results (the
Disclosures). Unless noted otherwise below or in the Disclosures,
no provisions have been established in respect of the claims
discussed below.
As
discussed in the Disclosures, the majority of claims involve highly
complex issues. Often these issues are subject to substantial
uncertainties and, therefore, the probability of a loss, if any,
being sustained and/or an estimate of the amount of any loss is
difficult to ascertain.
Unless
specifically identified below that a provision has been taken,
AstraZeneca considers each of the claims to represent a contingent
liability and discloses information with respect to the nature and
facts of the cases in accordance with IAS 37.
There
is one matter concerning legal proceedings in the Disclosures,
which is considered probable that an outflow will be required, but
for which we are unable to make an estimate of the possible loss or
range of possible losses at this stage.
In
cases that have been settled or adjudicated, or where quantifiable
fines and penalties have been assessed and which are not subject to
appeal, or where a loss is probable and we are able to make a
reasonable estimate of the loss, AstraZeneca records the loss
absorbed or makes a provision for its best estimate of the expected
loss. The position could change over time and the estimates that
the Company made, and upon which the Company have relied in
calculating these provisions are inherently imprecise. There can,
therefore, be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed the amount of the
provisions that have been booked in the accounts. The major factors
causing this uncertainty are described more fully in the
Disclosures and herein.
AstraZeneca
has full confidence in, and will vigorously defend and enforce, its
IP.
Matters disclosed in respect of the fourth quarter of 2022 and to 9
February 2023
Patent litigation
Calquence
US patent proceedings
As
previously disclosed, in February 2022, in response to Paragraph IV
notices from multiple ANDA filers, AstraZeneca filed patent
infringement lawsuits in the US District Court for the District of
Delaware. In its complaint, AstraZeneca alleges that a generic
version of Calquence, if
approved and marketed, would infringe patents listed in the US FDA
Orange Book with reference to Calquence that are owned or licensed by
AstraZeneca. Trial has been scheduled for March 2025.
In
February 2023, Sandoz Inc. filed a petition for inter partes review with the US Patent
and Trademark Office (USPTO) of certain Calquence patent claims in US Patent
No. 10,272,083 (the '083 patent)). AstraZeneca has asserted claims
for infringement of the '083 patent against Sandoz and other
defendants in the US ANDA litigation. AstraZeneca is considering
its response to Sandoz's petition before the
USPTO.
Farxiga
US patent proceedings
As
previously disclosed, in 2018, in response to Paragraph IV notices,
AstraZeneca initiated abbreviated new drug application (ANDA)
litigation against Zydus Pharmaceuticals (USA) Inc. (Zydus) in the
US District Court for the District of Delaware (the District
Court). In May 2021, trial against Zydus proceeded and in October
2021, the District Court issued a decision finding the asserted
claims of AstraZeneca's patent as valid and infringed by Zydus's
ANDA product. In August 2022, Zydus appealed the District Court's
decision. In November 2022, Zydus's appeal was dismissed.
Additional ANDA challenges are pending.
Imjudo
US patent proceedings
In
January 2023, Bristol-Myers Squibb Co. and E.R. Squibb & Sons,
LLC filed a lawsuit in US District Court for the District of
Delaware against AstraZeneca alleging that AstraZeneca's marketing
of Imjudo infringes two of
their patents.
Lokelma
US patent proceedings
As
previously disclosed, in August 2022, in response to Paragraph IV
notices, AstraZeneca initiated ANDA litigation against multiple
generic filers in the US District Court for the District of
Delaware. A trial has been scheduled for March 2025.
Symbicort
US patent proceedings
As
previously disclosed, AstraZeneca is involved in two ongoing ANDA
patent litigations with Mylan Pharmaceuticals Inc. (Mylan) and
Kindeva Drug Delivery L.P. (Kindeva) brought in the US District
Court for the Northern District of West Virginia (the District
Court). In one of those matters, in November 2022, the District
Court determined that the asserted patent was invalid. AstraZeneca
appealed that decision to the United States Court of Appeals for
the Federal Circuit (the Federal Circuit). With respect to the
other matter, following a stipulation of infringement and validity
by Mylan and Kindeva that was subject to certain appeal issues, in
December 2022, the District Court issued a Final Judgment in favour
of AstraZeneca. In December 2022, Mylan and Kindeva appealed the
Final Judgment to the Federal Circuit. Both appeals are scheduled
to be heard in March 2023.
Tagrisso
Patent proceedings outside the US
As
previously disclosed, in Russia in October 2021, AstraZeneca filed
a lawsuit in the Arbitration Court of the Moscow Region (the Court)
against Axelpharm, LLC to prevent it from obtaining authorisation
to market a generic version of Tagrisso prior to the expiration of
AstraZeneca's patents covering Tagrisso. The lawsuit also names the
Ministry of Health of the Russian Federation as a third party. In
March 2022, the Court dismissed the lawsuit. In June 2022, the
dismissal was affirmed on appeal. In January 2023, the dismissal
was affirmed on further appeal. AstraZeneca is considering its
option.
Lynparza
US patent proceedings
In
December 2022, AstraZeneca received a Paragraph IV notice letter
from an ANDA filer relating to patents listed in the FDA Orange
Book with reference to Lynparza. AstraZeneca is reviewing the
notice letter.
Product liability litigation
Byetta/Bydureon
US proceedings
As
previously disclosed, Amylin Pharmaceuticals, LLC (a wholly owned
subsidiary of AstraZeneca) and AstraZeneca are among multiple
defendants in various lawsuits filed in federal and state courts
involving claims of physical injury from treatment with
Byetta and/or Bydureon. The lawsuits allege several
types of injuries including pancreatic cancer and thyroid cancer. A
multidistrict litigation was established in the US District Court
for the Southern District of California (the District Court) in
regard to the alleged pancreatic cancer cases in federal courts.
Further, a coordinated proceeding has been established in Superior
Court in Los Angeles, California (the California Court) for cases
in California state courts. In March and April 2021, the District
Court and the California Court respectively granted Defendants'
summary judgment motions, dismissing all cases alleging pancreatic
cancer with prejudice. All remaining claims in both courts,
including those alleging thyroid cancer, have since been dismissed.
This matter is now concluded.
Nexium and
Losec/Prilosec
US proceedings
As
previously disclosed, AstraZeneca is defending various lawsuits
brought in US federal and state courts involving multiple
plaintiffs claiming that they have been diagnosed with various
injuries following treatment with proton pump inhibitors (PPIs),
including Nexium and
Prilosec. The vast majority
of these lawsuits relate to allegations of kidney injuries. In
August 2017, the pending federal court cases were consolidated in a
multidistrict litigation (MDL)
proceeding in the US District Court for the District of New Jersey
for pre-trial purposes. A bellwether trial has been scheduled for
June 2023, with subsequent bellwether trials scheduled for July and
September 2023. In addition to the MDL cases, there are cases filed
in several state courts around the US; a case that was previously
set to go to trial in Delaware state court was dismissed in October
2022.
Commercial Litigation
Anti-Terrorism Act Civil Lawsuit
As
previously disclosed, in October 2017, AstraZeneca and certain
other pharmaceutical and/or medical device companies were named as
defendants in a complaint filed in US District Court for the
District of Columbia (the District Court) by US nationals (or their
estates, survivors, or heirs) who were killed or wounded in Iraq
between 2005 and 2013. The plaintiffs allege that the defendants
violated the US Anti-Terrorism Act and various state laws by
selling pharmaceuticals and medical supplies to the Iraqi Ministry
of Health. In July 2020, the District Court granted AstraZeneca's
and the other defendants' motion and dismissed the lawsuit, and the
plaintiffs appealed to the DC Circuit Court of Appeals (the
Appellate Court). In January 2022, a panel of the Appellate Court
reversed the dismissal and remanded the case back to the District
Court. AstraZeneca and the other defendants filed petitions
requesting en banc review
by the entire Appellate Court, which were denied in February
2023.
Employment Litigation (US)
In
December 2022, AstraZeneca was served with a lawsuit filed by seven
former employees in the US District Court for the District of
Delaware asserting age, religion, and disability discrimination
claims related to AstraZeneca's COVID-19 vaccine mandate. These
claims are pled on a single-plaintiff and class action
basis.
Pay Equity Litigation (US)
AstraZeneca
is defending a putative class and collective action matter in the
US District Court for the Northern District of Illinois brought by
three named plaintiffs, who are former AstraZeneca pharmaceutical
sales representatives. The case involves claims under the federal
and Illinois Equal Pay Acts, with the plaintiffs alleging they were
paid less than male employees who performed substantially similar
and/or equal work. The plaintiffs seek various damages on behalf of
themselves and the putative class and/or collective, including
without limitation backpay, liquidated damages, compensatory and
punitive damages, attorneys' fees, and interest. In January 2023,
the District Court granted AstraZeneca's motion to dismiss
plaintiffs' complaint.
Government investigations/proceedings
Brazilian Operations Investigation (Brazil)
In May
2017, Brazilian authorities seized records and data from Alexion's
Brazil offices as part of an investigation being conducted into
Alexion's Brazilian operations. AstraZeneca cooperated with this
enquiry. The prosecutor recommended discontinuance in September
2022 after determining that there was insufficient evidence to
support a legal claim. The judicial authority approved
discontinuance of the investigation, without any further
enforcement action, in November 2022. This matter is now
concluded.
Texas Qui Tam
US proceedings
In
December 2022, AstraZeneca was served with an unsealed civil
lawsuit brought by a qui
tam relator on behalf of the State of Texas in Texas state
court, which alleges that AstraZeneca engaged in unlawful marketing
practices.
US 340B Litigations and Proceedings
US proceedings
As
previously disclosed, in January 2021, AstraZeneca filed a lawsuit
in US District Court for the District of Delaware (the District
Court) alleging that an Advisory Opinion issued by the Department
of Health and Human Services violates the Administrative Procedure
Act. AstraZeneca later amended its complaint to include allegations
challenging letters the US government issued in May 2021 asserting
that AstraZeneca's contract pharmacy policy violates the 340B
statute. In February 2022, the District Court ruled in favour of
AstraZeneca. In January 2023, the Court of Appeals affirmed the
District Court decision.
Note 7: Subsequent events
On 9
January 2023, it was announced that AstraZeneca had entered into a
definitive agreement to acquire CinCor Pharma, Inc., a US-based
clinical-stage biopharmaceutical company, focused on developing
novel treatments for resistant and uncontrolled hypertension as
well as chronic kidney disease. On 23 January 2023, AstraZeneca
initiated a tender offer to acquire all of CinCor's outstanding
shares for a price of $26 per share in cash at closing, plus a
non-tradable contingent value right of $10 per share in cash
payable upon a specified regulatory submission of a baxdrostat
product. Combined, the upfront and maximum potential contingent
value payments represent, if achieved, a transaction value of
approximately $1.8bn. As part of the transaction, AstraZeneca will
acquire the cash and marketable securities on CinCor's balance
sheet, which totalled approximately $522m as of 30 September 2022.
The transaction is expected to close in the first quarter of
2023.
On 16
January 2023, AstraZeneca completed the acquisition of Neogene
Therapeutics Inc. AstraZeneca acquired all outstanding equity of
Neogene for a total consideration of up to $320m, on a cash and
debt free basis. This includes an initial payment of $200m on deal
closing, and a further up to $120m in both contingent
milestones-based and non-contingent consideration.
On 30
January 2023, AstraZeneca completed the sale of its West Chester
site in Ohio, US, to National Resilience, Inc. On completion of the
sale, the Property, plant and equipment assets associated with this
transaction of $150m which were recorded as Assets held for sale as
at 31 December 2022 have been disposed of, with no net impact
recorded in the Consolidated statement of comprehensive
income.
On 2
February 2023, the Group entered into an additional $2.0bn of
two-year committed bank facilities.
Table 25: FY 2022 - Product Sales year-on-year
analysis77
The CER
information in respect of FY 2022 included in the Consolidated
Financial Information has not been audited by
PricewaterhouseCoopers LLP.
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
14,631
|
13
|
19
|
3,537
|
10
|
14
|
6,484
|
23
|
2,726
|
10
|
23
|
1,884
|
(5)
|
10
|
|
Tagrisso
|
5,444
|
9
|
15
|
1,567
|
17
|
22
|
2,007
|
13
|
1,023
|
4
|
17
|
847
|
(7)
|
8
|
|
Imfinzi
|
2,784
|
15
|
21
|
287
|
4
|
7
|
1,552
|
25
|
544
|
12
|
26
|
401
|
(1)
|
15
|
|
Lynparza
|
2,638
|
12
|
18
|
488
|
27
|
31
|
1,226
|
13
|
655
|
6
|
19
|
269
|
4
|
20
|
|
Calquence
|
2,057
|
66
|
69
|
45
|
n/m
|
n/m
|
1,657
|
52
|
286
|
n/m
|
n/m
|
69
|
n/m
|
n/m
|
|
Enhertu
|
79
|
n/m
|
n/m
|
51
|
n/m
|
n/m
|
-
|
-
|
21
|
n/m
|
n/m
|
7
|
n/m
|
n/m
|
|
Orpathys
|
33
|
n/m
|
n/m
|
33
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Zoladex
|
927
|
(2)
|
6
|
657
|
6
|
12
|
15
|
15
|
133
|
(10)
|
1
|
122
|
(28)
|
(15)
|
|
Faslodex
|
334
|
(22)
|
(14)
|
159
|
(4)
|
3
|
17
|
(45)
|
55
|
(52)
|
(46)
|
103
|
(15)
|
1
|
|
Iressa
|
114
|
(38)
|
(34)
|
94
|
(38)
|
(35)
|
9
|
(19)
|
2
|
(52)
|
(41)
|
9
|
(44)
|
(35)
|
|
Arimidex
|
99
|
(29)
|
(24)
|
76
|
(29)
|
(26)
|
-
|
-
|
-
|
(87)
|
(86)
|
23
|
(23)
|
(11)
|
|
Casodex
|
78
|
(45)
|
(40)
|
53
|
(50)
|
(47)
|
-
|
-
|
1
|
(49)
|
(48)
|
24
|
(31)
|
(19)
|
|
Others
|
44
|
(14)
|
(6)
|
27
|
(6)
|
1
|
1
|
59
|
6
|
(4)
|
4
|
10
|
(36)
|
(26)
|
|
BioPharmaceuticals: CVRM*
|
9,188
|
13
|
19
|
4,119
|
9
|
15
|
2,479
|
11
|
1,906
|
25
|
40
|
684
|
10
|
25
|
|
Farxiga
|
4,381
|
46
|
56
|
1,665
|
39
|
47
|
1,071
|
46
|
1,297
|
60
|
81
|
348
|
32
|
49
|
|
Brilinta
|
1,358
|
(8)
|
(4)
|
286
|
(13)
|
(10)
|
744
|
1
|
282
|
(18)
|
(8)
|
46
|
(27)
|
(22)
|
|
Lokelma
|
289
|
65
|
75
|
20
|
n/m
|
n/m
|
170
|
47
|
30
|
n/m
|
n/m
|
69
|
55
|
83
|
|
Roxadustat
|
197
|
13
|
18
|
197
|
13
|
18
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa*
|
150
|
5
|
14
|
-
|
-
|
-
|
77
|
(32)
|
41
|
41
|
58
|
32
|
n/m
|
n/m
|
|
Crestor
|
1,048
|
(4)
|
2
|
794
|
2
|
9
|
65
|
(19)
|
41
|
(21)
|
(12)
|
148
|
(21)
|
(10)
|
|
Seloken/Toprol-XL
|
862
|
(9)
|
(4)
|
839
|
(10)
|
(4)
|
-
|
n/m
|
14
|
26
|
27
|
9
|
(16)
|
(13)
|
|
Bydureon
|
280
|
(27)
|
(26)
|
3
|
(16)
|
(18)
|
242
|
(24)
|
35
|
(37)
|
(29)
|
-
|
(95)
|
(94)
|
|
Onglyza
|
257
|
(28)
|
(25)
|
121
|
(32)
|
(28)
|
76
|
(13)
|
38
|
(37)
|
(29)
|
22
|
(32)
|
(30)
|
|
Others
|
366
|
(10)
|
(7)
|
194
|
(1)
|
4
|
34
|
(35)
|
128
|
(12)
|
(10)
|
10
|
(32)
|
(24)
|
|
BioPharmaceuticals: R&I
|
5,765
|
(4)
|
-
|
1,443
|
(18)
|
(14)
|
2,655
|
10
|
1,054
|
(15)
|
(5)
|
613
|
(3)
|
7
|
|
Symbicort
|
2,538
|
(7)
|
(2)
|
608
|
-
|
5
|
973
|
(9)
|
582
|
(13)
|
(3)
|
375
|
(2)
|
5
|
|
Fasenra
|
1,396
|
11
|
15
|
43
|
n/m
|
n/m
|
906
|
15
|
305
|
7
|
20
|
142
|
(12)
|
(1)
|
|
Breztri
|
398
|
96
|
n/m
|
92
|
68
|
75
|
239
|
n/m
|
33
|
n/m
|
n/m
|
34
|
32
|
56
|
|
Saphnelo
|
116
|
n/m
|
n/m
|
-
|
-
|
-
|
111
|
n/m
|
2
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Tezspire
|
4
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
|
Pulmicort
|
645
|
(33)
|
(31)
|
462
|
(40)
|
(39)
|
65
|
(9)
|
69
|
(6)
|
6
|
49
|
5
|
15
|
|
Daliresp/Daxas
|
189
|
(17)
|
(16)
|
3
|
(28)
|
(24)
|
176
|
(15)
|
9
|
(39)
|
(32)
|
1
|
3
|
7
|
|
Bevespi
|
58
|
7
|
9
|
5
|
31
|
38
|
42
|
7
|
10
|
(7)
|
5
|
1
|
n/m
|
n/m
|
|
Others
|
421
|
(29)
|
(27)
|
230
|
(20)
|
(17)
|
143
|
32
|
42
|
(77)
|
(75)
|
6
|
(53)
|
(46)
|
|
BioPharmaceuticals: V&I
|
4,736
|
2
|
8
|
1,316
|
(43)
|
(41)
|
1,168
|
n/m
|
1,027
|
(33)
|
(24)
|
1,225
|
68
|
89
|
|
Vaxzevria
|
1,798
|
(54)
|
(52)
|
729
|
(67)
|
(67)
|
79
|
24
|
365
|
(65)
|
(61)
|
625
|
8
|
17
|
|
Evusheld
|
2,185
|
n/m
|
n/m
|
413
|
n/m
|
n/m
|
1,067
|
n/m
|
298
|
n/m
|
n/m
|
407
|
n/m
|
n/m
|
|
Synagis
|
578
|
41
|
59
|
173
|
n/m
|
n/m
|
1
|
(94)
|
213
|
5
|
17
|
191
|
28
|
51
|
|
FluMist
|
175
|
(31)
|
(20)
|
1
|
(51)
|
(54)
|
21
|
(21)
|
151
|
(32)
|
(20)
|
2
|
(4)
|
(10)
|
|
Rare Disease*
|
7,053
|
4
|
10
|
431
|
(10)
|
6
|
4,324
|
8
|
1,428
|
(3)
|
9
|
870
|
8
|
24
|
|
Soliris*
|
3,762
|
(11)
|
(5)
|
301
|
(29)
|
(10)
|
2,180
|
(7)
|
805
|
(21)
|
(12)
|
476
|
11
|
24
|
|
Ultomiris*
|
1,965
|
34
|
42
|
38
|
n/m
|
n/m
|
1,136
|
35
|
481
|
49
|
68
|
310
|
6
|
26
|
|
Strensiq*
|
958
|
16
|
18
|
35
|
41
|
31
|
769
|
19
|
78
|
(3)
|
9
|
76
|
(1)
|
16
|
|
Koselugo
|
208
|
93
|
96
|
26
|
n/m
|
n/m
|
162
|
55
|
20
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Kanuma*
|
160
|
16
|
19
|
31
|
73
|
61
|
77
|
12
|
44
|
(3)
|
10
|
8
|
21
|
38
|
|
Other medicines
|
1,625
|
(5)
|
4
|
788
|
(14)
|
(9)
|
144
|
(16)
|
123
|
(28)
|
(24)
|
570
|
28
|
50
|
|
Nexium
|
1,285
|
(3)
|
8
|
568
|
(19)
|
(13)
|
120
|
(6)
|
46
|
(26)
|
(17)
|
551
|
28
|
50
|
|
Others
|
340
|
(10)
|
(7)
|
220
|
4
|
7
|
24
|
(45)
|
77
|
(29)
|
(27)
|
19
|
37
|
54
|
|
Total Product Sales
|
42,998
|
18
|
24
|
11,634
|
(4)
|
1
|
17,254
|
44
|
8,264
|
9
|
22
|
5,846
|
22
|
40
|
Table 26: Q4 2022 - Product Sales year-on-year
analysis78
The Q4
2022 information in respect of the three months ended 31 December
2022 included in the Consolidated Financial Information has not
been audited by PricewaterhouseCoopers LLP.
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
3,746
|
9
|
18
|
814
|
4
|
14
|
1,789
|
23
|
689
|
4
|
21
|
454
|
(13)
|
7
|
|
Tagrisso
|
1,342
|
2
|
12
|
356
|
10
|
22
|
535
|
10
|
245
|
(5)
|
10
|
206
|
(16)
|
4
|
|
Imfinzi
|
752
|
19
|
27
|
63
|
(4)
|
3
|
450
|
37
|
142
|
3
|
20
|
97
|
(4)
|
18
|
|
Lynparza
|
689
|
10
|
17
|
130
|
27
|
33
|
331
|
13
|
162
|
-
|
16
|
66
|
(7)
|
15
|
|
Calquence
|
588
|
49
|
53
|
17
|
n/m
|
n/m
|
465
|
39
|
86
|
n/m
|
n/m
|
20
|
n/m
|
n/m
|
|
Enhertu
|
28
|
n/m
|
n/m
|
17
|
n/m
|
n/m
|
-
|
-
|
8
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Orpathys
|
(1)
|
n/m
|
n/m
|
(1)
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Zoladex
|
210
|
(9)
|
4
|
149
|
(3)
|
10
|
4
|
71
|
33
|
(6)
|
10
|
24
|
(42)
|
(25)
|
|
Faslodex
|
74
|
(27)
|
(14)
|
38
|
(14)
|
(2)
|
1
|
(76)
|
11
|
(46)
|
(38)
|
24
|
(23)
|
(3)
|
|
Iressa
|
24
|
(32)
|
(24)
|
19
|
(34)
|
(26)
|
3
|
55
|
-
|
(44)
|
21
|
2
|
(52)
|
(44)
|
|
Arimidex
|
14
|
(57)
|
(50)
|
10
|
(61)
|
(56)
|
-
|
-
|
-
|
-
|
-
|
4
|
(39)
|
(27)
|
|
Casodex
|
16
|
(28)
|
(16)
|
10
|
(27)
|
(16)
|
-
|
-
|
1
|
n/m
|
n/m
|
5
|
(38)
|
(23)
|
|
Others
|
10
|
(29)
|
(18)
|
6
|
(18)
|
(6)
|
-
|
-
|
1
|
(8)
|
(10)
|
3
|
(40)
|
(31)
|
|
BioPharmaceuticals: CVRM
|
2,281
|
12
|
22
|
938
|
8
|
20
|
696
|
15
|
493
|
25
|
44
|
154
|
(11)
|
6
|
|
Farxiga
|
1,177
|
39
|
52
|
441
|
39
|
52
|
323
|
42
|
342
|
52
|
76
|
71
|
(8)
|
9
|
|
Brilinta
|
345
|
(1)
|
4
|
64
|
(11)
|
(6)
|
206
|
16
|
67
|
(19)
|
(6)
|
8
|
(48)
|
(41)
|
|
Lokelma
|
81
|
50
|
63
|
6
|
n/m
|
n/m
|
48
|
40
|
9
|
98
|
n/m
|
18
|
18
|
49
|
|
Roxadustat
|
49
|
65
|
87
|
49
|
66
|
87
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa
|
39
|
-
|
14
|
-
|
-
|
-
|
15
|
(51)
|
12
|
37
|
63
|
12
|
n/m
|
n/m
|
|
Crestor
|
224
|
(13)
|
(2)
|
164
|
(8)
|
4
|
15
|
(28)
|
11
|
24
|
42
|
34
|
(33)
|
(18)
|
|
Seloken/Toprol-XL
|
157
|
(23)
|
(12)
|
150
|
(24)
|
(13)
|
-
|
-
|
4
|
n/m
|
n/m
|
3
|
(23)
|
(30)
|
|
Bydureon
|
73
|
(20)
|
(20)
|
-
|
(51)
|
(59)
|
66
|
(16)
|
7
|
(47)
|
(38)
|
-
|
(49)
|
(98)
|
|
Onglyza
|
52
|
(31)
|
(24)
|
22
|
(20)
|
(8)
|
16
|
(38)
|
9
|
(37)
|
(26)
|
5
|
(36)
|
(32)
|
|
Others
|
84
|
(13)
|
(6)
|
42
|
(6)
|
6
|
7
|
(42)
|
32
|
(11)
|
(8)
|
3
|
(13)
|
(3)
|
|
BioPharmaceuticals: R&I
|
1,447
|
(9)
|
(3)
|
341
|
(23)
|
(16)
|
692
|
7
|
259
|
(23)
|
(10)
|
155
|
(5)
|
10
|
|
Symbicort
|
620
|
(9)
|
(2)
|
133
|
(13)
|
(3)
|
255
|
(2)
|
137
|
(20)
|
(7)
|
95
|
(2)
|
11
|
|
Fasenra
|
381
|
7
|
12
|
13
|
n/m
|
n/m
|
257
|
10
|
76
|
2
|
18
|
35
|
(18)
|
(2)
|
|
Breztri
|
116
|
59
|
68
|
21
|
44
|
66
|
75
|
59
|
11
|
n/m
|
n/m
|
9
|
8
|
34
|
|
Saphnelo
|
48
|
n/m
|
n/m
|
-
|
-
|
-
|
46
|
n/m
|
1
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
|
Tezspire
|
4
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
|
Pulmicort
|
166
|
(33)
|
(28)
|
123
|
(36)
|
(32)
|
12
|
(37)
|
19
|
(19)
|
(7)
|
12
|
(5)
|
11
|
|
Daliresp/Daxas
|
28
|
(52)
|
(52)
|
1
|
(53)
|
(49)
|
25
|
(54)
|
2
|
(39)
|
(30)
|
-
|
-
|
-
|
|
Bevespi
|
14
|
(5)
|
(1)
|
1
|
28
|
46
|
10
|
(1)
|
3
|
(27)
|
(15)
|
-
|
-
|
-
|
|
Others
|
70
|
(53)
|
(47)
|
49
|
(36)
|
(27)
|
12
|
(20)
|
8
|
(86)
|
(83)
|
1
|
(57)
|
(43)
|
|
BioPharmaceuticals: V&I
|
1,129
|
(51)
|
(44)
|
321
|
(74)
|
(72)
|
226
|
n/m
|
334
|
(49)
|
(40)
|
248
|
(25)
|
(7)
|
|
Vaxzevria
|
85
|
(95)
|
(94)
|
45
|
(96)
|
(95)
|
-
|
-
|
40
|
(87)
|
(84)
|
-
|
-
|
-
|
|
Evusheld
|
734
|
n/m
|
n/m
|
246
|
n/m
|
n/m
|
217
|
n/m
|
99
|
50
|
74
|
172
|
n/m
|
n/m
|
|
Synagis
|
194
|
(19)
|
(3)
|
29
|
46
|
77
|
(1)
|
n/m
|
90
|
(26)
|
(14)
|
76
|
(21)
|
(3)
|
|
FluMist
|
116
|
(35)
|
(24)
|
1
|
(39)
|
(43)
|
10
|
n/m
|
105
|
(39)
|
(27)
|
-
|
(88)
|
(86)
|
|
Rare Disease
|
1,816
|
4
|
10
|
116
|
(12)
|
2
|
1,149
|
10
|
349
|
(6)
|
7
|
202
|
(1)
|
19
|
|
Soliris
|
844
|
(22)
|
(16)
|
83
|
(29)
|
(12)
|
491
|
(19)
|
179
|
(26)
|
(15)
|
91
|
(18)
|
(4)
|
|
Ultomiris
|
593
|
52
|
62
|
4
|
(6)
|
8
|
365
|
71
|
134
|
34
|
53
|
90
|
23
|
52
|
|
Strensiq
|
272
|
24
|
27
|
10
|
59
|
48
|
224
|
29
|
19
|
(1)
|
13
|
19
|
(6)
|
16
|
|
Koselugo
|
58
|
74
|
77
|
3
|
n/m
|
n/m
|
48
|
51
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Kanuma
|
49
|
45
|
44
|
16
|
n/m
|
n/m
|
21
|
18
|
10
|
(8)
|
4
|
2
|
68
|
n/m
|
|
Other medicines
|
379
|
(7)
|
7
|
180
|
1
|
12
|
32
|
(11)
|
28
|
(23)
|
(19)
|
139
|
(12)
|
11
|
|
Nexium
|
300
|
(9)
|
7
|
131
|
1
|
13
|
26
|
(12)
|
9
|
(40)
|
(32)
|
134
|
(13)
|
9
|
|
Others
|
79
|
(1)
|
5
|
49
|
1
|
8
|
6
|
(2)
|
19
|
(12)
|
(10)
|
5
|
34
|
70
|
|
Total Product Sales
|
10,798
|
(6)
|
2
|
2,710
|
(25)
|
(18)
|
4,584
|
19
|
2,152
|
(12)
|
1
|
1,352
|
(13)
|
6
|
Table 27: Collaboration Revenue
|
|
|
FY 2022
|
FY 2021
|
|
|
|
$m
|
$m
|
|
Enhertu: alliance revenue
|
|
519
|
193
|
|
Tezspire: alliance revenue
|
|
79
|
-
|
|
Lynparza: regulatory milestones
|
|
355
|
-
|
|
Lynparza: sales milestones
|
|
-
|
400
|
|
Tralokinumab:
sales milestones
|
|
110
|
-
|
|
Vaxzevria: royalties
|
|
76
|
64
|
|
Other
royalty income
|
|
72
|
74
|
|
Other
Collaboration Revenue
|
|
142
|
145
|
|
Total
|
|
1,353
|
876
|
Table 28: Other Operating Income and Expense
|
|
|
FY 2022
|
FY 2021
|
|
|
|
$m
|
$m
|
|
Brazikumab
licence termination funding
|
|
138
|
99
|
|
Waltham
site gain on sale and leaseback
|
|
125
|
-
|
|
Divestment
of rights to Plendil
|
|
61
|
-
|
|
Divestment
of Viela Bio, Inc. shareholding
|
|
-
|
776
|
|
Crestor (Europe ex-UK and Spain)
|
|
-
|
317
|
|
Late
stage small-molecule antibiotics assets (ex-US)
|
|
-
|
100
|
|
Other
|
|
190
|
200
|
|
Total
|
|
514
|
1,492
|
Other shareholder information
Financial calendar
Announcement
of first quarter 2023
results
27 April 2023
Announcement of
half year and second quarter 2023 results
28 July
2023
Announcement of
year to date and third quarter 2023 results
9 November
2023
Dividends
are normally paid as follows:
First
interim:
Announced with the half year results and paid in
September
Second
interim:
Announced with full
year results and paid in March
The
record date for the second interim dividend for 2022, payable on 27
March 2023, will be 24 February 2023. The ex-dividend date will be
23 February 2023.
Contacts
For
details on how to contact the Investor Relations Team, please
click
here. For Media contacts, click
here.
Addresses for correspondence
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2
0AA
|
Equiniti
Limited
Aspect
House
Spencer
Road
Lancing
West
Sussex
BN99
6DA
|
Euroclear
Sweden AB PO Box 191
SE-101
23 Stockholm
|
American
Stock Transfer
6201
15th Avenue
Brooklyn
NY
11219
|
|
United
Kingdom
|
United
Kingdom
|
Sweden
|
United
States
|
|
|
|
|
|
|
+44 (0)
20 3749 5000
|
0800
389 1580
|
+46 (0)
8 402 9000
|
+1
(888) 697 8018
|
|
|
+44 (0)
121 415 7033
|
|
+1
(718) 921 8137
|
|
|
|
|
db@astfinancial.com
|
Trademarks
Trademarks
of the AstraZeneca group of companies appear throughout this
document in italics. Medical publications also appear throughout
the document in italics. AstraZeneca, the AstraZeneca logotype and
the AstraZeneca symbol are all trademarks of the AstraZeneca group
of companies. Trademarks of companies other than AstraZeneca that
appear in this document include Arimidex and Casodex, owned by AstraZeneca or
Juvisé (depending on geography); Beyfortus, a trademark of Sanofi
Pasteur Inc.; Enhertu, a trademark of Daiichi
Sankyo; Losec, owned by AstraZeneca or Cheplapharm (depending
upon geography); Seloken,
owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending on
geography); Synagis,
owned by AstraZeneca or Sobi aka Swedish Orphan Biovitrum AB
(publ). (depending on geography); and Tezspire, a trademark of Amgen,
Inc.
Information
on or accessible through AstraZeneca's websites, including
astrazeneca.com,
does not form part of and is not incorporated into this
announcement.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Disease, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com
and follow the Company on Twitter @AstraZeneca.
Cautionary statements regarding forward-looking
statements
In
order, among other things, to utilise the 'safe harbour' provisions
of the US Private Securities Litigation Reform Act of 1995,
AstraZeneca (hereafter 'the Group') provides the following
cautionary statement:
This
document contains certain forward-looking statements with respect
to the operations, performance and financial condition of the
Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group's
control, include, among other things:
Nothing in this document, or any related presentation/webcast,
should be construed as a profit forecast. There can be no
guarantees that the conditions to the closing of the proposed
transaction with CinCor will be satisfied on the expected timetable
or at all or that baxdrostat or any combination product will
receive the necessary regulatory approvals or prove to be
commercially successful if approved.
- End
of document –
1 Constant
exchange rates. The differences between Actual Change and CER
Change are due to foreign exchange movements between periods in
2022 vs 2021. CER financial measures are not accounted for
according to generally accepted accounting principles (GAAP)
because they remove the effects of currency movements from Reported
results.
5 Cardiovascular,
Renal and Metabolism.
6 FY 2022 growth rates
on medicines acquired with Alexion have been calculated on a pro
forma basis comparing to the corresponding period in the prior
year. In FY 2022, Total Revenue from Koselugo is included in Rare Disease
(FY 2021: Oncology) and Total Revenue from Andexxa is included in
BioPharmaceuticals: CVRM (FY 2021: Rare Disease). The growth rate
shown for each therapy area has been calculated as though these
changes had been implemented in FY 2021.
7 Respiratory &
Immunology.
8 The COVID-19
medicines are Vaxzevria,
Evusheld, and AZD3152
– the COVID-19 antibody currently in
development.
10 Metastatic
castration-resistant prostate cancer.
11 Human epidermal
growth factor receptor 2.
12 Hepatocellular
carcinoma.
13 Non-small cell lung
cancer.
19 In Table 2,
the plus and minus symbols denote the directional impact of the
item being discussed, e.g. a ‘+’ symbol next to a
R&D expense comment indicates that the item increased the
R&D expense relative to the prior year.
28 Imfinzi Product Sales includes sales of
Imjudo, which commenced in
Q4 2022.
49 Betaloc is the brand name for
Seloken in
China.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
AstraZeneca PLC
|
Date: 09 February 2023
|
|
By: /s/ Adrian Kemp
|
|
|
Name: Adrian Kemp
|
|
|
Title: Company Secretary
|